JP5677970B2 - 新規cc−1065類似体およびその複合体 - Google Patents
新規cc−1065類似体およびその複合体 Download PDFInfo
- Publication number
- JP5677970B2 JP5677970B2 JP2011535528A JP2011535528A JP5677970B2 JP 5677970 B2 JP5677970 B2 JP 5677970B2 JP 2011535528 A JP2011535528 A JP 2011535528A JP 2011535528 A JP2011535528 A JP 2011535528A JP 5677970 B2 JP5677970 B2 JP 5677970B2
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- formula
- compound
- independently
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical class C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims description 526
- 125000000217 alkyl group Chemical group 0.000 claims description 130
- 229910052799 carbon Inorganic materials 0.000 claims description 111
- 125000001424 substituent group Chemical group 0.000 claims description 97
- -1 C (O) OH Inorganic materials 0.000 claims description 96
- 229910052717 sulfur Inorganic materials 0.000 claims description 95
- 229910052739 hydrogen Inorganic materials 0.000 claims description 88
- 125000003118 aryl group Chemical group 0.000 claims description 81
- 229910052760 oxygen Inorganic materials 0.000 claims description 73
- 230000004568 DNA-binding Effects 0.000 claims description 69
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 60
- 102000004190 Enzymes Human genes 0.000 claims description 45
- 108090000790 Enzymes Proteins 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 125000006850 spacer group Chemical group 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 37
- 125000005647 linker group Chemical group 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 31
- 125000001425 triazolyl group Chemical group 0.000 claims description 30
- 150000004820 halides Chemical class 0.000 claims description 26
- 150000002148 esters Chemical class 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 239000000758 substrate Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 14
- 239000000651 prodrug Substances 0.000 claims description 14
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 12
- 238000003379 elimination reaction Methods 0.000 claims description 11
- 125000005905 mesyloxy group Chemical group 0.000 claims description 11
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 11
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 10
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 claims description 10
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 10
- 108010073969 valyllysine Proteins 0.000 claims description 10
- 229910052727 yttrium Inorganic materials 0.000 claims description 10
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 claims description 9
- WEZNQZHACPSMEF-UHFFFAOYSA-N 6-amino-2-[[2-(2-aminopropanoylamino)-3-phenylpropanoyl]amino]hexanoic acid Chemical compound NCCCCC(C(O)=O)NC(=O)C(NC(=O)C(N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-UHFFFAOYSA-N 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 9
- 238000007254 oxidation reaction Methods 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 6
- 150000007857 hydrazones Chemical class 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 108090000712 Cathepsin B Proteins 0.000 claims description 4
- 102000004225 Cathepsin B Human genes 0.000 claims description 4
- 102000005600 Cathepsins Human genes 0.000 claims description 4
- 108010084457 Cathepsins Proteins 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052720 vanadium Inorganic materials 0.000 claims description 4
- 125000006653 (C1-C20) heteroaryl group Chemical group 0.000 claims description 3
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 3
- 102000002464 Galactosidases Human genes 0.000 claims description 3
- 108010093031 Galactosidases Proteins 0.000 claims description 3
- 108010060309 Glucuronidase Proteins 0.000 claims description 3
- 102000053187 Glucuronidase Human genes 0.000 claims description 3
- 102000004459 Nitroreductase Human genes 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 230000001146 hypoxic effect Effects 0.000 claims description 3
- 108020001162 nitroreductase Proteins 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 description 84
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 75
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 125000004429 atom Chemical group 0.000 description 50
- 125000003827 glycol group Chemical group 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 49
- 206010028980 Neoplasm Diseases 0.000 description 45
- 229940088598 enzyme Drugs 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 41
- 229920001223 polyethylene glycol Chemical group 0.000 description 41
- 239000002202 Polyethylene glycol Chemical group 0.000 description 40
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 38
- 0 CI1C2=*C*2C(*)(C(*)*)c(c(C(*)=C(*)*2)c2c(*)c2*)c2N(*)C1(*)* Chemical compound CI1C2=*C*2C(*)(C(*)*)c(c(C(*)=C(*)*2)c2c(*)c2*)c2N(*)C1(*)* 0.000 description 37
- 125000005842 heteroatom Chemical group 0.000 description 37
- 238000000034 method Methods 0.000 description 36
- 230000000144 pharmacologic effect Effects 0.000 description 35
- 239000003153 chemical reaction reagent Substances 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 32
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 30
- 238000003776 cleavage reaction Methods 0.000 description 30
- 230000036961 partial effect Effects 0.000 description 30
- 230000008685 targeting Effects 0.000 description 30
- 230000007017 scission Effects 0.000 description 29
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 22
- 239000000427 antigen Substances 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 229920006395 saturated elastomer Polymers 0.000 description 22
- 230000007118 DNA alkylation Effects 0.000 description 21
- 125000000524 functional group Chemical group 0.000 description 20
- 125000003396 thiol group Chemical group [H]S* 0.000 description 20
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 19
- 235000013477 citrulline Nutrition 0.000 description 19
- 229960002173 citrulline Drugs 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 241000124008 Mammalia Species 0.000 description 18
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000002776 aggregation Effects 0.000 description 15
- 238000004220 aggregation Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 14
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000005804 alkylation reaction Methods 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- 125000004434 sulfur atom Chemical group 0.000 description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 10
- 230000029936 alkylation Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 10
- 238000007363 ring formation reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 9
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 230000002152 alkylating effect Effects 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 231100001274 therapeutic index Toxicity 0.000 description 8
- 244000180577 Sambucus australis Species 0.000 description 7
- 235000018734 Sambucus australis Nutrition 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 230000000269 nucleophilic effect Effects 0.000 description 7
- 239000000816 peptidomimetic Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000006352 cycloaddition reaction Methods 0.000 description 6
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 125000006574 non-aromatic ring group Chemical group 0.000 description 6
- 150000002482 oligosaccharides Polymers 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 150000001266 acyl halides Chemical class 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 125000000837 carbohydrate group Chemical group 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 150000003852 triazoles Chemical class 0.000 description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 125000003172 aldehyde group Chemical group 0.000 description 4
- 150000001336 alkenes Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
- 229960005501 duocarmycin Drugs 0.000 description 4
- 229930184221 duocarmycin Natural products 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 150000002540 isothiocyanates Chemical class 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 125000005454 tryptophanyl group Chemical group 0.000 description 4
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000004970 halomethyl group Chemical group 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 125000004474 heteroalkylene group Chemical group 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 3
- 150000002466 imines Chemical group 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- NINOYJQVULROET-UHFFFAOYSA-N n,n-dimethylethenamine Chemical group CN(C)C=C NINOYJQVULROET-UHFFFAOYSA-N 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- WEZNQZHACPSMEF-SNPRPXQTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-SNPRPXQTSA-N 0.000 description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 2
- 125000006599 (C1-C3) alkylaminocarbonylamino group Chemical group 0.000 description 2
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 description 2
- 125000006596 (C1-C3) alkylcarbonyloxy group Chemical group 0.000 description 2
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- ROJBIOJYHVAOFT-UHFFFAOYSA-N 2-(disulfanyl)pyridine Chemical class SSC1=CC=CC=N1 ROJBIOJYHVAOFT-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 101800003344 Vaccinia growth factor Proteins 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RCFDIXKVOHJQPP-UHFFFAOYSA-N furo[2,3-b]pyridine Chemical compound C1=CN=C2OC=CC2=C1 RCFDIXKVOHJQPP-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 150000002390 heteroarenes Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 125000000743 hydrocarbylene group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940060367 inert ingredients Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 229950003063 mitumomab Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000000405 phenylalanyl group Chemical group 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920000412 polyarylene Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- PHQXWZGXKAFWAZ-DQYPLSBCSA-N (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoic acid Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 PHQXWZGXKAFWAZ-DQYPLSBCSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 description 1
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- ZFXBERJDEUDDMX-UHFFFAOYSA-N 1,2,3,5-tetrazine Chemical group C1=NC=NN=N1 ZFXBERJDEUDDMX-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- VLYNPUIDQHROHG-UHFFFAOYSA-N 1,3-azaphosphinine Chemical group C1=CN=CP=C1 VLYNPUIDQHROHG-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical group 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- DLKQHBOKULLWDQ-UHFFFAOYSA-N 1-bromonaphthalene Chemical compound C1=CC=C2C(Br)=CC=CC2=C1 DLKQHBOKULLWDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- UFCRQKWENZPCAD-UHFFFAOYSA-N 2-(2-aminophenyl)propanamide Chemical compound NC(=O)C(C)C1=CC=CC=C1N UFCRQKWENZPCAD-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- SDMAQFGBPOJFOM-UHFFFAOYSA-N 2-[[2-(2-aminopropanoylamino)-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCCC(NC(=O)C(N)C)C(=O)NC(CCCN=C(N)N)C(O)=O SDMAQFGBPOJFOM-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- YLLRPQWLASQXSI-UHFFFAOYSA-N 3-(4b,8a,9,9a-tetrahydro-4aH-pyrido[2,3-b]indol-4-ylamino)phenol Chemical compound Oc1cccc(NC2=CC=NC3NC4C=CC=CC4C23)c1 YLLRPQWLASQXSI-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical class NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- AWZKCUCQJNTBAD-UHFFFAOYSA-N 6-amino-2-[[2-(2-aminopropanoylamino)-4-methylpentanoyl]amino]hexanoic acid Chemical compound CC(N)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CCCCN AWZKCUCQJNTBAD-UHFFFAOYSA-N 0.000 description 1
- MHHAWNPHDLCPLF-UHFFFAOYSA-N 6-amino-2-[[2-[(2-amino-3-methylbutanoyl)amino]-3-phenylpropanoyl]amino]hexanoic acid Chemical compound NCCCCC(C(O)=O)NC(=O)C(NC(=O)C(N)C(C)C)CC1=CC=CC=C1 MHHAWNPHDLCPLF-UHFFFAOYSA-N 0.000 description 1
- AEMPCGRFEZTWIF-UHFFFAOYSA-N 6-amino-2-[[2-[(2-amino-3-methylbutanoyl)amino]-4-methylpentanoyl]amino]hexanoic acid Chemical compound CC(C)C(N)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(O)=O AEMPCGRFEZTWIF-UHFFFAOYSA-N 0.000 description 1
- RBRNEFJTEHPDSL-UHFFFAOYSA-N 6-amino-2-[[2-[(2-amino-3-phenylpropanoyl)amino]-3-phenylpropanoyl]amino]hexanoic acid Chemical compound C=1C=CC=CC=1CC(N)C(=O)NC(C(=O)NC(CCCCN)C(O)=O)CC1=CC=CC=C1 RBRNEFJTEHPDSL-UHFFFAOYSA-N 0.000 description 1
- YLEIWGJJBFBFHC-UHFFFAOYSA-N 6-amino-2-[[2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]hexanoic acid Chemical compound NCCCCC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- QXRNAOYBCYVZCD-BQBZGAKWSA-N Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN QXRNAOYBCYVZCD-BQBZGAKWSA-N 0.000 description 1
- PHQXWZGXKAFWAZ-ZLIFDBKOSA-N Ala-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 PHQXWZGXKAFWAZ-ZLIFDBKOSA-N 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- FGZKQRYLKNETPS-UHFFFAOYSA-N CC(C)C1C(C)=NCC1O Chemical compound CC(C)C1C(C)=NCC1O FGZKQRYLKNETPS-UHFFFAOYSA-N 0.000 description 1
- NADZOWSHYOQXJO-UHFFFAOYSA-N CC(C1CC2)C(C3C=CC(CC4=[O](C)C4)=CC3)NC1=CC2C1CC1 Chemical compound CC(C1CC2)C(C3C=CC(CC4=[O](C)C4)=CC3)NC1=CC2C1CC1 NADZOWSHYOQXJO-UHFFFAOYSA-N 0.000 description 1
- XMQQXXUXKSRMCF-UHFFFAOYSA-N CCC(NS[IH]S[IH][IH]CCCC(C)(C)S)=C Chemical compound CCC(NS[IH]S[IH][IH]CCCC(C)(C)S)=C XMQQXXUXKSRMCF-UHFFFAOYSA-N 0.000 description 1
- MFVKSERBUQQSJG-UHFFFAOYSA-N CCCC1C#CCC1C Chemical compound CCCC1C#CCC1C MFVKSERBUQQSJG-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- 102100035893 CD151 antigen Human genes 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102100024175 Centriole, cilia and spindle-associated protein Human genes 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 229920008712 Copo Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 102100039128 DNA-3-methyladenine glycosylase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055334 EphB2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010036449 HLA-DR10 antigen Proteins 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000980796 Homo sapiens Centriole, cilia and spindle-associated protein Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000744174 Homo sapiens DNA-3-methyladenine glycosylase Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 description 1
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 1
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000596404 Homo sapiens Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101001129851 Homo sapiens Paired immunoglobulin-like type 2 receptor alpha Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000650590 Homo sapiens Roundabout homolog 4 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- ISDGSCMWKLWMIC-RYUDHWBXSA-N NC(=O)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 Chemical compound NC(=O)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ISDGSCMWKLWMIC-RYUDHWBXSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- FDTZNKNDXMRDQS-UHFFFAOYSA-N PNPCl Chemical compound PNPCl FDTZNKNDXMRDQS-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100031651 Paired immunoglobulin-like type 2 receptor alpha Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101800005164 Peptide V Proteins 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100027701 Roundabout homolog 4 Human genes 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical group C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100026160 Tomoregulin-2 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 1
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- QTXGUIMEHKCPBH-FHWLQOOXSA-N Val-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 QTXGUIMEHKCPBH-FHWLQOOXSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- UIGRBLXJJABSCB-UHFFFAOYSA-N benzo[e]indol-4-one Chemical compound O=C1C=C2C=CC=CC2=C2C1=NC=C2 UIGRBLXJJABSCB-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- ZSCYJHGJGRSPAB-UHFFFAOYSA-N carbamic acid Chemical compound NC(O)=O.NC(O)=O ZSCYJHGJGRSPAB-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 229940125880 compound 4j Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- YWKVMGDEOUPQGN-UHFFFAOYSA-N ethyl 2-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C#CC1(O)C(CC2)CCN2C1 YWKVMGDEOUPQGN-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical group [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- ALAGDBVXZZADSN-UHFFFAOYSA-N pentazine Chemical group C1=NN=NN=N1 ALAGDBVXZZADSN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 description 1
- 229920000768 polyamine Chemical group 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000006265 spirocyclization reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Description
本発明は、DNA結合アルキル化剤CC−1065の新規な類似体およびその複合体に関する。さらに、本発明は上記薬剤および複合体を調製するための中間体に関する。複合体は、1以上の活性化段階の後におよび/または複合体により制御された速度および時間に亘りその(複数の)ペイロード(payload)を放出するように設計され、それによって上記DNAアルキル化剤の1種以上を選択的に送達および/または制御可能に放出する。上記薬剤、複合体および中間体は、望ましくない(細胞)増殖を特徴とする疾病を治療するために用いることができる。例としては、本発明の薬剤および複合体は腫瘍の治療に用いることができる。
ストレプトミセス(Streptomyces)種の培養ブロスから最初に単離されたデュオカルマイシンは、CC−1065をも含む抗腫瘍抗生物質ファミリーのメンバーである。これらの非常に強力な薬剤は、マイナーグルーブ中のアデニンのN3でDNAを配列選択的にアルキル化する能力からその生物活性を得ると言われており、これはアポトーシス細胞死機序で終結する一連の現象を開始する1。
本発明は、式(I)若しくは(II)の化合物:
R2,R2',R3,R3',R4,R4',R12およびR19は独立してH,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Ra,SRa,S(O)Ra,S(O)2Ra,S(O)ORa,S(O)2ORa,OS(O)Ra,OS(O)2Ra,OS(O)ORa,OS(O)2ORa,ORa,NHRa,N(Ra)Rb,+N(Ra)(Rb)Rc,P(O)(ORa)(ORb),OP(O)(ORa)(ORb),SiRaRbRc,C(O)Ra,C(O)ORa,C(O)N(Ra)Rb,OC(O)Ra,OC(O)ORa,OC(O)N(Ra)Rb,N(Ra)C(O)Rb,N(Ra)C(O)ORbおよびN(Ra)C(O)N(Rb)Rcから選択される、
(Ra,Rb,およびRcは独立してHおよび任意に置換されたC1-3アルキルまたはC1-3へテロアルキルから選択される)
またはR3+R3'および/若しくはR4+R4'は独立して、=O,=S,=NOR18,=C(R18)R18'および=NR18から選択され(R18およびR18'は独立してHおよび任意に置換されたC1-3アルキルから選択される)、R2,R2',R3,R3',R4,R4'およびR12の2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
X2はO、C(R14)(R14')およびNR14'から選択される(R14およびR14'はR7の定義と同じ意味を有し独立して選択される、またはR14'およびR7'は、R7'およびR14'を有すると指定される原子間の二重結合の結果存在しない);
R5,R5',R6,R6',R7,およびR7'は独立してH,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Re,SRe,S(O)Re,S(O)2Re,S(O)ORe,S(O)2ORe,OS(O)Re,OS(O)2Re,OS(O)ORe,OS(O)2ORe,ORe,NHRe,N(Re)Rf,+N(Re)(Rf)Rg,P(O)(ORe)(ORf),OP(O)(ORe)(ORf),SiReRfRg,C(O)Re,C(O)ORe,C(O)N(Re)Rf,OC(O)Re,OC(O)ORe,OC(O)N(Re)Rf,N(Re)C(O)Rf,N(Re)C(O)ORf,N(Re)C(O)N(Rf)Rgおよび水溶性基から選択される、
(Re、RfおよびRgは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-15アルキル,C1-15へテロアルキル,C3-15シクロアルキル,C1-15ヘテロシクロアルキル,C5-15アリールまたはC1-15ヘテロアリールから選択され(eeは1から1000まで選択され、X13はO,S,およびNRf1から選択される)(Rf1およびRe1は独立してHおよびC1-3アルキルから選択される)、Re,Rfおよび/またはRgにおける任意の置換基の1つ以上は任意に水溶性基であり、Re,RfおよびRgの2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する)
またはR5+R5'および/若しくはR6+R6'および/若しくはR7+R7'は独立して、=O,=S,=NORe3,=C(Re3)Re4および=NRe3から選択されるか(Re3およびRe4は独立してHおよび任意に置換されたC1-3アルキルから選択される)、またはR5'+R6'および/若しくはR6'+R7'および/若しくはR7'+R14'は、R5'およびR6',および/若しくはR6'およびR7',および/若しくはR7'およびR14'をそれぞれ有すると指定された原子間の二重結合の結果存在せず、R5,R5',R6,R6',R7,R7',R14,およびR14'の2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
X1はO,S,およびNR13から選択され(R13はHおよび任意に置換されたC1-8アルキルまたはC1-8へテロアルキルから選択され、あらゆる他の置換基と結合しない);
X3はO,S,C(R15)R15',−C(R15)(R15')−C(R15'')(R15''')−,−N(R15)−N(R15')−,−C(R15)(R15')−N(R15'')−,−N(R15'')−C(R15)(R15')−,−C(R15)(R15')−O−,−O−C(R15)(R15')−,−C(R15)(R15')−S−,−S−C(R15)(R15')−,−C(R15)=C(R15')−,=C(R15)−C(R15')=,−N=C(R15')−,=N−C(R15')=,−C(R15)=N−,=C(R15)−N=,−N=N−,=N−N=,CR15,NおよびNR15から選択されるか、またはDB1およびDB2において-X3-は-X3aおよびX3b-を示し(X3aはX34に結合し、二重結合がX34とX4との間に存在し、X3bはX11に結合する)(X3aは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-8アルキルまたはC1-8ヘテロアルキルから選択され、あらゆる他の置換基と結合しない);
X4はO,S,C(R16)R16',NR16,NおよびCR16から選択され;
X5はO,S,C(R17)R17',NOR17およびNR17から選択され(R17およびR17'は独立してHおよび任意に置換されたC1-8アルキルまたはC1-8へテロアルキルから選択され、あらゆる他の置換基と結合しない);
X6はCR11,CR11(R11'),N,NR11,OおよびSから選択され;
X7はCR8,CR8(R8'),N,NR8,OおよびSから選択され;
X8はCR9,CR9(R9'),N,NR9,OおよびSから選択され;
X9はCR10,CR10(R10'),N,NR10,OおよびSから選択され;
X10はCR20,CR20(R20'),N,NR20,OおよびSから選択され;
X11はC,CR21およびNから選択される、またはX11-X3bはCR21,CR21(R21'),N,NR21,OおよびSから選択され;
X12はC,CR22およびNから選択され;
X6*,X7*,X8*,X9*,X10*およびX11*はそれぞれX6,X7,X8,X9,X10およびX11の定義と同じ意味を有し、独立して選択され;
X34はC,CR23およびNから選択され;
DB6およびDB7においてX11*の環B原子は環Aの環原子に、DB6およびDB7において環Aと環Bとが単結合により直接結合するように結合し;
R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23はそれぞれ独立してH,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Rh,SRh,S(O)Rh,S(O)2Rh,S(O)ORh,S(O)2ORh,OS(O)Rh,OS(O)2Rh,OS(O)ORh,OS(O)2ORh,ORh,NHRh,N(Rh)Ri,+N(Rh)(Ri)Rj,P(O)(ORh)(ORi),OP(O)(ORh)(ORi),SiRhRiRj,C(O)Rh,C(O)ORh,C(O)N(Rh)Ri,OC(O)Rh,OC(O)ORh,OC(O)N(Rh)Ri,N(Rh)C(O)Ri,N(Rh)C(O)ORi,N(Rh)C(O)N(Ri)Rj,および水溶性基から選択され、
(Rh,RiおよびRjは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-15アルキル,C1-15へテロアルキル,C3-15シクロアルキル,C1-15へテロシクロアルキル,C5-15アリールまたはC1-15ヘテロアリールから選択され、Rh,Riおよび/またはRjにおける任意の置換基の1つ以上は任意に水溶性基であり、Rh,RiおよびRjの2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する)
またはR8+R8'および/若しくはR9+R9’および/若しくはR10+R10'および/若しくはR11+R11'および/若しくはR15+R15'および/若しくはR15''+R15'''および/若しくはR16+R16'および/若しくはR20+R20'および/若しくはR21+R21'は独立して=O,=S,=NORh1,=C(Rh1)Rh2および=NRh1から選択され(Rh1およびRh2は独立してHおよび任意に置換されたC1-3アルキルから選択される)、R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23の2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
R8bおよびR9bは独立して選択されてR8と同じ意味を有する、ただしこれらはあらゆる他の置換基と結合してはならない;
R4およびR4'の1つ並びにR16およびR16'の1つは任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成してもよく;
R2,R2',R3およびR3'の1つ並びにR5およびR5'の1つは任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成してもよく;並びに
aおよびbは独立して0および1から選択される。
a)DB部分はDA1,DA2,DA1’またはDA2’部分を含まず;および
b)DB1における環Bはヘテロ環であり;および
c)DB1におけるX3が-X3aおよびX3b-を表しかつBが芳香族であるときは、上記環B上の2つの隣接する置換基は結合して、上記環Bに縮合する任意に置換された炭素環またはヘテロ環を形成し;および
d)DB2におけるX3が-X3aおよびX3b-を表しかつBが芳香族であるときは、上記環B上の2つの隣接する置換基は結合して、上記環Bに縮合する任意に置換されたヘテロ環、上記環Bに縮合する任意に置換された非芳香族炭素環、または置換された芳香族炭素環(上記環Bに縮合し、かつ結合している少なくとも1つの置換基はヒドロキシ基,第1級アミノ基若しくは第2級アミノ基を含み、上記第1級若しくは第2級アミンは芳香環系における環原子でもアミドの一部でもない)を形成し;
e)DB2における環Aが6員環芳香環であるときは、環B上の置換基は結合せずに環Bに縮合する環を形成せず;および
f)DB8における環A上の2つの隣接する置換基は結合して上記環Aに縮合する任意に置換された炭素環またはヘテロ環を形成して二環式部分を形成し、これにはさらなる環は結合せず;および
g)DB9における環Aと上記環Aに縮合するあらゆる環は少なくとも2つの環ヘテロ原子を有する。
(ここで
V2は存在しないかまたは官能基部分であり;
各L2は独立して、存在しないかまたはV2をLに連結する連結基であり;
各Lは独立して、存在しないかまたはL2を1つ以上のV1および/若しくはYに連結する連結基であり;
各V1は独立して、存在しない、または条件的に切断可能な若しくは条件的に変換可能な部分であって化学的、光化学的、物理的、生物学的若しくは酵素的方法で切断若しくは変換されてよく;
各Yは独立して、存在しない、または自己脱離スペーサー系であって1つ以上の自己脱離スペーサーを含み、かつV1、場合によりL、および1つ以上のZと連結し;
各pおよびqは分岐度を示す数で、それぞれ独立して正の整数であり;
zはZについての結合部位の合計数以下である正の整数であり;
各Zは独立して上で定義した式(I)、(II)、(I’)または(II’)の化合物であって、ここでX1,R5,R5',R6,R6',R7,R7',R14,R14',R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23の1つ以上は任意にさらに式(V)により置換されてもよく、または式(V)の置換基であってよく:
各Zは独立して、X1、またはR5,R5',R6,R6',R7,R7',R14,R14',R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22,R23における原子、またはこれらR置換基のいずれかを有している原子を通じてYに結合し;並びに
少なくともV2かV1は存在する)。
RMは活性部分であり、L,V1,Y,Z,pおよびzは上で定義した通りであるが、ただしLはここではRMを1つ以上のV1および/またはYに連結しており、V1,YおよびZは保護基を有してよく、上で定義した通りZにおいて任意に存在する1つ以上のV2'-L2'部分は任意に独立して活性部分であるRM'であってもよく、また(IV)に1を超える活性部分がある場合には、いくつかのまたはすべての反応部分は同一であるか異なる。これらの式(IV)の連結物質の結合体は式(III)の化合物についての中間体であるとみなしてもよいし、みなしてはならない。
他に定義しない限り、本明細書中で用いるすべての技術用語および科学用語は当業者により一般に理解されるものと同じ意味を有する。
本発明は、DNAアルキル化試剤CC−1065の新規な類似体に関する。本発明の試剤は、望ましくない(細胞)増殖を特徴とする疾患を治療するのに用いられると考えられる。たとえば、本発明の試剤は、腫瘍、癌、自己免疫疾患または感染症を治療するのに用いることができる。
R2,R2',R3,R3',R4,R4',R12およびR19は独立して、H,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Ra,SRa,S(O)Ra,S(O)2Ra,S(O)ORa,S(O)2ORa,OS(O)Ra,OS(O)2Ra,OS(O)ORa,OS(O)2ORa,ORa,NHRa,N(Ra)Rb,+N(Ra)(Rb)Rc,P(O)(ORa)(ORb),OP(O)(ORa)(ORb),SiRaRbRc,C(O)Ra,C(O)ORa,C(O)N(Ra)Rb,OC(O)Ra,OC(O)ORa,OC(O)N(Ra)Rb,N(Ra)C(O)Rb,N(Ra)C(O)ORbおよびN(Ra)C(O)N(Rb)Rcから選択され、
(Ra,Rb,およびRcは独立して、Hおよび任意に置換されたC1-3アルキルまたはC1-3へテロアルキルから選択される)
またはR3+R3'および/若しくはR4+R4'は独立して、=O,=S,=NOR18,=C(R18)R18'および=NR18から選択され(R18およびR18'は独立して、Hおよび任意に置換されたC1-3アルキルから選択される)、R2,R2',R3,R3',R4,R4'およびR12のうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
X2はO、C(R14)(R14')およびNR14'から選択され(R14およびR14'はR7の定義と同じ意味を有し独立して選択される、またはR14'およびR7'は、R7'およびR14'を有すると指定される原子間の二重結合の結果存在しない);
R5,R5',R6,R6',R7,およびR7'は独立して、H,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Re,SRe,S(O)Re,S(O)2Re,S(O)ORe,S(O)2ORe,OS(O)Re,OS(O)2Re,OS(O)ORe,OS(O)2ORe,ORe,NHRe,N(Re)Rf,+N(Re)(Rf)Rg,P(O)(ORe)(ORf),OP(O)(ORe)(ORf),SiReRfRg,C(O)Re,C(O)ORe,C(O)N(Re)Rf,OC(O)Re,OC(O)ORe,OC(O)N(Re)Rf,N(Re)C(O)Rf,N(Re)C(O)ORf,N(Re)C(O)N(Rf)Rgおよび水溶性基から選択され、
(Re、RfおよびRgは独立して、Hおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-15アルキル,C1-15へテロアルキル,C3-15シクロアルキル,C1-15ヘテロシクロアルキル,C5-15アリールまたはC1-15ヘテロアリールから選択され(eeは1ないし1000から選択され、X13はO,S,およびNRf1から選択される)(Rf1およびRe1は独立して、HおよびC1-3アルキルから選択される)、Re,Rfおよび/またはRgにおける任意の置換基のうち1つ以上は任意に水溶性基であり、Re,RfおよびRgのうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する)
またはR5+R5'および/若しくはR6+R6'および/若しくはR7+R7'は独立して、=O,=S,=NORe3,=C(Re3)Re4および=NRe3から選択されるか(Re3およびRe4は独立して、Hおよび任意に置換されたC1-3アルキルから選択される)、またはR5'+R6'および/若しくはR6'+R7'および/若しくはR7'+R14'は、R5'およびR6',および/若しくはR6'およびR7',および/若しくはR7'およびR14'をそれぞれ有すると指定された原子間の二重結合の結果存在せず、R5,R5',R6,R6',R7,R7',R14,およびR14'のうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
X1はO,S,およびNR13から選択され(R13はHおよび任意に置換されたC1-8アルキルまたはC1-8へテロアルキルから選択され、あらゆる他の置換基と結合しない);
X3はO,S,C(R15)R15',−C(R15)(R15')−C(R15'')(R15''')−,−N(R15)−N(R15')−,−C(R15)(R15')−N(R15'')−,−N(R15'')−C(R15)(R15')−,−C(R15)(R15')−O−,−O−C(R15)(R15')−,−C(R15)(R15')−S−,−S−C(R15)(R15')−,−C(R15)=C(R15')−,=C(R15)−C(R15')=,−N=C(R15')−,=N−C(R15')=,−C(R15)=N−,=C(R15)−N=,−N=N−,=N−N=,CR15,NおよびNR15から選択されるか、またはDB1およびDB2において-X3-は-X3aおよびX3b-を示し(X3aはX34に結合し、二重結合がX34とX4との間に存在し、X3bはX11に結合する)(X3aは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-8アルキルまたはC1-8ヘテロアルキルから選択され、あらゆる他の置換基と結合しない);
X4はO,S,C(R16)R16',NR16,NおよびCR16から選択され;
X5はO,S,C(R17)R17',NOR17およびNR17から選択され(R17およびR17'は独立してHおよび任意に置換されたC1-8アルキルまたはC1-8へテロアルキルから選択され、あらゆる他の置換基と結合しない);
X6はCR11,CR11(R11'),N,NR11,OおよびSから選択され;
X7はCR8,CR8(R8'),N,NR8,OおよびSから選択され;
X8はCR9,CR9(R9'),N,NR9,OおよびSから選択され;
X9はCR10,CR10(R10'),N,NR10,OおよびSから選択され;
X10はCR20,CR20(R20'),N,NR20,OおよびSから選択され;
X11はC,CR21およびNから選択される、またはX11-X3bはCR21,CR21(R21'),N,NR21,OおよびSから選択され;
X12はC,CR22およびNから選択され;
X6*,X7*,X8*,X9*,X10*およびX11*はそれぞれX6,X7,X8,X9,X10およびX11の定義と同じ意味を有し、独立して選択され;
X34はC,CR23およびNから選択され;
DB6およびDB7においてX11*の環B原子は環Aの環原子に、DB6およびDB7において環Aと環Bとが単結合により直接結合するように結合し;
R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23はそれぞれ独立してH,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Rh,SRh,S(O)Rh,S(O)2Rh,S(O)ORh,S(O)2ORh,OS(O)Rh,OS(O)2Rh,OS(O)ORh,OS(O)2ORh,ORh,NHRh,N(Rh)Ri,+N(Rh)(Ri)Rj,P(O)(ORh)(ORi),OP(O)(ORh)(ORi),SiRhRiRj,C(O)Rh,C(O)ORh,C(O)N(Rh)Ri,OC(O)Rh,OC(O)ORh,OC(O)N(Rh)Ri,N(Rh)C(O)Ri,N(Rh)C(O)ORi,N(Rh)C(O)N(Ri)Rj,および水溶性基から選択され、
(Rh,RiおよびRjは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-15アルキル,C1-15へテロアルキル,C3-15シクロアルキル,C1-15へテロシクロアルキル,C5-15アリールまたはC1-15ヘテロアリールから選択され、Rh,Riおよび/またはRjにおける任意の置換基のうち1つ以上は任意に水溶性基であり、Rh,RiおよびRjのうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する)
またはR8+R8'および/若しくはR9+R9’および/若しくはR10+R10'および/若しくはR11+R11'および/若しくはR15+R15'および/若しくはR15''+R15'''および/若しくはR16+R16'および/若しくはR20+R20'および/若しくはR21+R21'は独立して、=O,=S,=NORh1,=C(Rh1)Rh2および=NRh1から選択され(Rh1およびRh2は独立して、Hおよび任意に置換されたC1-3アルキルから選択される)、R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23のうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
R8bおよびR9bは独立して選択され、R8と同じ意味を有する、ただしこれらはあらゆる他の置換基と結合してはならない;
R4およびR4'の1つ並びにR16およびR16'の1つは任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成してもよく;
R2,R2',R3およびR3'の1つ並びにR5およびR5'の1つは任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成してもよく;並びに
aおよびbは独立して0および1から選択される。
a)DB部分はDA1、DA2、DA1’またはDA2’部分を含まず;および
b)DB1における環Bはヘテロ環であり;および
c)DB1におけるX3が-X3aおよびX3b-を示しかつ環Bが芳香族であるときは、上記環B上の2つの隣接する置換基は結合して、上記環Bに縮合する任意に置換された炭素環またはヘテロ環を形成し;および
d)DB2におけるX3が-X3aおよびX3b-を示しかつBが芳香族であるときは、上記環B上の2つの隣接する置換基は結合して、上記環Bに縮合する任意に置換されたヘテロ環、上記環Bに縮合する任意に置換された非芳香族炭素環、または置換された芳香族炭素環(上記環Bに縮合し、かつ結合している少なくとも1つの置換基はヒドロキシ基,第1級アミノ基若しくは第2級アミノ基を有し、上記第1級若しくは第2級アミンは芳香環系における環原子でもアミドの一部でもない)を形成し;および
e)DB2における環Aが6員環芳香環であるときは、環B上の置換基は結合せずに環Bに縮合する環を形成せず;および
f)DB8における環A上の2つの隣接する置換基は結合して上記環Aに縮合する任意に置換された炭素環またはヘテロ環を形成して二環式部分を形成し、これにはさらなる環は縮合せず;および
g)DB9における環Aと上記環Aに縮合するあらゆる環は少なくとも2つの環ヘテロ原子を有する。
例として肝臓における高まった代謝的分解(metabolic degradation)は、たとえば、DNA結合ユニットにおいて比較的容易に酸化されうる基、たとえばアセチレン部分およびアルケン部分の導入によって達成できる。毒性化合物の酸化は、哺乳動物がこのような化合物を無毒化しうるメカニズムのうちの1つである。本発明の化合物が肝臓で吸収されると、効率的な無毒化はたとえば副作用としての肝臓毒性を回避することができる。
でありうる。
でありうる。
さらなる実施形態において、部分DB2はたとえば
さらなる実施形態において、部分DB3はたとえば
さらなる実施形態において、部分DB5はたとえば
さらなる実施形態において、部分DB6はたとえば
(jj、jj'、およびjj''は独立して0ないし8から選択され、各tt、tt'、およびtt''は独立して0および1から選択され、各X21およびX22は独立してO、S、NR67、H2、およびC(R67)R68(R67およびR68は独立してHおよび任意に置換されたC1-3アルキルまたはC1-3へテロアルキルから選択される)から選択され、R66はH、COOH、CO2Me、OH、OMe、NR69R70、NR69C(O)CH3、SH、SMe、
さらなる実施形態において、部分DB8はたとえば
でありうる。
さらなる実施形態において、部分DB9はたとえば
R8+R8'および/若しくはR9+R9’および/若しくはR10+R10'および/若しくはR11+R11'および/若しくはR15+R15'および/若しくはR15''+R15'''および/若しくはR16+R16'および/若しくはR20+R20'および/若しくはR21+R21'は独立して、=O,=S,=NORh1,=C(Rh1)Rh2および=NRh1(Rh1およびRh2は独立してHおよび任意に置換されたC1-3アルキルから選択される)から選択され、R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23のうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する。
他の態様において、本発明はインビボで1つ以上の工程で式(I)または(II)の化合物にそれぞれ変換できる、式(I)または(II)の化合物の複合体に関する。また、この複合体は、式(I)または(II)の化合物の誘導体にも変換することができ、この複合体における式(I)または(II)の化合物に結合したプロ部分の一部は、インビボでの変換後、式(I)または(II)の化合物に結合したままである。このことを別の方法で考察すると、リンカーの残りの部分が、式(I)または(II)の化合物の一部であるということである。
V2は存在しないかまたは官能基部分であり;
各L2は独立して、存在しないかまたはV2をLに連結する連結基であり;
各Lは独立して、存在しないかまたはL2を1つ以上のV1および/若しくはYに連結する連結基であり;
各V1は独立して、存在しない、または条件的に切断可能な若しくは条件的に変換可能な部分であって化学的、光化学的、物理的、生物学的若しくは酵素的方法で切断若しくは変換されてよく;
各Yは独立して、存在しない、または自己脱離スペーサー系であって1つ以上の自己脱離スペーサーを含み、かつV1、任意にL、および1つ以上のZと連結し;
各pおよびqは分岐度を示す数で、それぞれ独立して正の整数であり;
zはZについての結合部位の合計数以下である正の整数であり;
各Zは独立して上で規定した化合物であり、ここでX1,R5,R5',R6,R6',R7,R7',R14,R14',R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22およびR23の1つ以上は任意にさらに式(V)により置換されてもよく、または式(V)の置換基であってもよく
各Zは独立して、X1、またはR5,R5',R6,R6',R7,R7',R14,R14',R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R20,R20',R21,R21',R22,R23における原子、またはこれらR置換基のいずれかを有している原子を通じてYに結合し;並びに
少なくともV2かV1は存在する)。
V2は存在しかつ標的化部分であるように選択され、および少なくとも1つの式(V)の基(V1'部分を有し、かつ1つのX14(CH2CH2O)ggCH2CH2X14部分(ggは3ないし1000から選択され、各X14は独立して以下
または当該式(V)の基は少なくとも2つのX14(CH2CH2O)ggCH2CH2X14部分(ここで各X14は独立して選択される)を有する。
RMは活性部分であり、L,V1,Y,Z,pおよびzは上でで定義した通りであるが、ただしLはここではRMを1つ以上のV1および/またはYに連結しており、V1,YおよびZは保護基を有してよく、上で定義した通りZにおいて任意に存在する1つ以上のV2'-L2'部分は任意に独立して活性部分であるRM'であってもよく、また(IV)に1を超える活性部分がある場合には、いくつかのまたはすべての反応部分は同一であるか異なる)。式(IV)のこれらのリンカー−試剤の複合体は、式(III)の化合物の中間体と見なされても見なされなくてもよい。式(IV)の化合物では、V1が存在しても存在しなくてもよい一方で、RMは存在しなければならない。
式(III)または(IV)の化合物において、V1部分は、条件的に切断可能な若しくは変換可能な基である。換言すれば、それは、ある条件中にまたはある条件下に置かれたときに、化学的、光化学的、物理的、生物学的、または酵素的プロセスによって変換されるか、および/または、Yから切断されるように設計される。この条件は、例えば、本発明の化合物を水性環境中におきV1の加水分解を導くこと、または、本発明の化合物をV1を認識し切断する酵素を含む環境中におくこと、または、本発明の化合物を還元条件下におき、V1の還元および/または除去を導くこと、または、本発明の化合物を酸化条件下におき、V1の酸化および/または除去を導くこと、または、本発明の化合物を例えばUV光のような放射線と接触させ、変換および/または切断を導くこと、または、本発明の化合物を熱と接触させ、変換および/または切断を導くこと、または、本発明の化合物を減圧下におき、変換、例えば逆環化付加(retrocycloaddition)および/または切断を導くこと、または、本発明の化合物を上昇圧または高圧化におき、変換および/または切断を導くことであってよい。この条件は、本発明の化合物を動物、例えば、哺乳類、例えば、ヒトに投与した後に満たされ得る:この条件は、例えば、内部要因(例えば、標的特異性酵素または低酸素)の存在または外部要因の適用(例えば、放射線、磁場)によって、該化合物が、例えば特定の器官、組織、細胞、細胞下の標的、または細菌、ウイルス、または微生物標的に局在化するときに満たされうる、またはこの条件は、投与後直ぐに既に満たされうる(例えば、循環中の偏在性酵素)。
一つの実施形態において、V1は、細胞外酵素のための基質を含む。
他の実施形態において、V1は、細胞内酵素のための基質を含む。
さらに他の実施形態において、V1は、リソソームの酵素のための基質を含む。
さらに他の実施形態において、V1は、セリンプロテアーゼプラスミンのための基質を含む。
さらに他の実施形態において、V1は、一以上のカテプシン、例えばカテプシンBのための基質を含む。
さらに他の実施形態において、V1は、ガラクトシダーゼのための基質を含む。
さらに他の実施形態において、V1は、キノンレダクターゼNQO1のための基質を含む。
さらに他の実施形態において、V1は、細胞内で加水分解されるヒドラジド、ヒドラゾンまたはイミン部分を含む。
さらに他の実施形態において、V1は、細胞内で切断されるジスルフィド部分を含む。
他の実施形態において、V2、L2、L、およびYは非存在であり、p、q、およびzは全て1である。
さらなる他の実施形態において、V1は、化学的に除去可能な基である。
さらなる他の実施形態において、V1は、X1を介してZに結合された化学的に除去可能な基である。
さらなる他の実施形態において、V1は、X1を介してZに結合されたベンジル基である。
他の実施形態において、V1は、tert-ブトキシカルボニル(メチルアミノ)エチル(メチルアミノ)カルボニルである。
他の実施形態において、V1は、4-(tert-ブトキシカルボニル)ピペラジン-1-カルボニルである。
1つの実施形態において、V1は、V1上の二以上の官能基を介してLと結合される。
他の実施形態において、V1は、V1上の一つの官能基を介してLと結合される。
他の実施形態において、V1はV1の天然または非天然アミノ酸の一つの側鎖における官能基を介してLと結合される。
他の実施形態において、V1のN-末端アミノ酸は、そのαアミノ基を介してLに結合される。
他の実施形態において、V1は存在しない。
自己脱離スペーサー系Yは、存在する場合、V1および任意にLを一以上の部分Zに連結する。
ここで、
WおよびXはそれぞれ、同じであるかまたは異なる、単一放出1、2+2n電気的カスケードスペーサー(n≧1)であり;
Aは、環化によって環状ウレウム誘導体を形成する、ω-アミノ アミノカルボニル環化スペーサーであり;
sは0または1であり;
wおよびxは、重合度を表す数であり、独立して、0(含む)から5(含む)の整数である。
Q’は、−R110C=CR111−、S、O、NR111、−R111C=N−、および−N=CR111−から選択され;
Bは、NR112、O、およびSから選択され;
PはC(R108)(R109)Qであり;
R106、R107、B、および(T−)t(T’−)t’(T’’−)t’’Pは、Bおよび(T−)t(T’−)t’(T’’−)t’’Pが、二つの隣接する炭素原子若しくはCaおよびCdのそれぞれに連結されるように、Ca、Cb、Cc、およびCdに連結され;
Qは非存在であるか、または−O−C(O)−であり;
t、t’、およびt’’は、重合度を表す数であり、独立して0(含む)から5(含む)の整数であり;
T、T’、およびT’’は、独立して下式を有する部分から選択される:
uは0または1の整数であり;
R115およびR116は独立して、Hおよび任意に置換されたC1−6アルキルから選択され;
R117、R118、R119、R120、R121、およびR122は独立して、H、OH、SH、NH2、N3、NO2、NO、CF3、CN、C(O)NH2、C(O)H、C(O)OH、ハロゲン、Rz、SRz、S(O)Rz、S(O)2Rz、S(O)ORz、S(O)2ORz、OS(O)Rz、OS(O)2Rz、OS(O)ORz、OS(O)2ORz、ORz、NHRz、N(Rz)Rz1、+N(Rz)(Rz1)Rz2、P(O)(ORz)(ORz1)、OP(O)(ORz)(ORz1)、C(O)Rz、C(O)ORz、C(O)N(Rz1)Rz、OC(O)Rz、OC(O)ORz、OC(O)N(Rz)Rz1、N(Rz1)C(O)Rz、N(Rz1)C(O)ORz、およびN(Rz1)C(O)N(Rz2)Rzから選択され、ここで、Rz、Rz1、およびRz2は独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1、C1−20アルキル、C1−20ヘテロアルキル、C3−20シクロアルキル、C1−20ヘテロシクロアルキル、C5−20アリール、またはC1−20ヘテロアリールから選択され、ここで、eeは、1〜1000から選択され、X13は、O、S、およびNRf1から選択され、並びに、Rf1およびRe1は独立してHおよびC1−3アルキルから選択され、Rz、Rz1、およびRz2の二以上は、任意に一以上の結合によって連結されて一以上の任意に置換された炭素環および/またはヘテロ環を形成し、置換基R115、R116、R117、R118、R119、R120、R121、およびR122の二以上は、任意に一以上の結合によって連結されて一以上の任意に置換された炭素環および/またはヘテロ環を形成する。
連結基Lは1つ以上のV1および/またはY部分をL2またはRMと連結する。LがV1と結合しており、その化合物が早い分解を受けにくい場合、合成はより容易であろう。LとYの結合は、V1をより簡単に変換および/または切断することができるという利点を有する。LとYを結合させる他の理由は、例えば、V1の切断の際にY(の一部)がLと結合したまま残り、これが反応性小分子の放出を阻止するため、或いは、その化合物が改善された(薬物動態学的)特性、溶解性または凝集挙動を示すためである。Lは、V1またはYをL2かまたはRMと直接連結する結合であってよい。しかし、他の態様では、Lは1つ以上の部分V1/YとL2またはRM部分を官能的に連結するかまたはスペースをもたせる連結基である。式(IV)の化合物では、例えば官能部分が結合されている場合、スペースを空けることは、反応性部分RMが反応パートナーに接近しやすくすることができる。式(III)の化合物では、スペースを空けることは、V2をさらに取り除くことができ(特にV1の酵素的な切断または変換の場合に)、V1を変換および/または切断する速度を向上させることができるので、より良好なV1のアクセス性を提供することができる。
X101およびX102はそれぞれ独立してO、NR131またはSであり、
各X103およびX104はそれぞれ独立してO、NR132またはSであり、
各xa、xb、xcおよびxdは独立して0または1であり、
kkは分岐度を表す数であり、1(含む)〜128(含む)から選択される整数であり、
llは分岐度を表す数であり、0(含む)〜127(含む)から選択される整数であり、
kk+ll≦128であり、
各DDは独立してH、OHまたは離脱基であり、
R130は樹枝状、分岐のまたは分岐しない多価部分のいずれかであり、任意に置換されたアルキレン、オリゴアルキレンまたはポリアルキレン、および任意に置換されたヘテロアルキレン、オリゴヘテロアルキレンまたはポリヘテロアルキレン、および任意に置換されたアリーレン、オリゴアリーレンまたはポリアリーレン、および任意に置換されたヘテロアリーレン、オリゴヘテロアリーレンまたはポリヘテロアリーレン、および任意に置換されたシクロアルキレン、オリゴシクロアルキレンまたはポリシクロアルキレン、および任意に置換されたヘテロシクロアルキレン、オリゴヘテロシクロアルキレンまたはポリヘテロシクロアルキレン、および−(CH2CH2O)v−、−アルキレン−(CH2CH2O)v−、−(CH2CH2O)v−アルキレン−、−アルキレン−(CH2CH2O)v−アルキレン−、−ヘテロアルキレン−(CH2CH2O)v−、−(CH2CH2O)v−ヘテロアルキレン−、−ヘテロアルキレン−(CH2CH2O)v−アルキレン−、−ヘテロアルキレン−(CH2CH2O)v−ヘテロアルキレン−、−アルキレン−(CH2CH2O)v−ヘテロアルキレン−、X14(CH2CH2O)ggCH2CH2X14、樹枝状構造物およびオリゴペプチド、または上記のうちの2つ以上の任意の組合せから選択され、
R131およびR132は独立して、H、C1−8アルキルおよびC1−8ヘテロアルキルから選択され、
vは1(含む)〜500(含む)から選択される)。
式(IV)の化合物の反応性部分RMは連結基Lと結合しており、反応パートナー上の適切な官能基と反応することができる。
X35はハライド、ヒドロキシ、OC(O)RddおよびOC(O)ORddから選択されるか、C(O)−X35は活性エステルであり、
X36は、ハライド、メシルオキシ、トリフリルオキシおよびトシルオキシから選択され、Rddは任意に置換されたC1−10アルキル、C1−10ヘテロアルキル、C3−10シクロアルキル、C1−10ヘテロシクロアルキル、C5−10アリールから選択される)。
部分V2は官能部分であり、これは本発明の化合物にさらなる官能性を付与するることを意味する。
ここで、fは0、1または2であり、gは0または1であり、およびPMは、L’にそのN末端で結合したアミノ酸またはペプチドである。
ここで、fは0、1または2であり、gは0または1であり、PMは、バリルシトルリン、バリルリジン、フェニルアラニルリジン、アラニルフェニルアラニルリジン、およびL'に対してそのN末端でカップリングされたD−アラニルフェニルアラニルリジンから選択され、gg'は3から1000または500または100または50または10または5まで選択される。
qは1から20までにわたり、rr、rr'、およびrr''は各々独立して0から8までにわたり、各X40およびX41は独立してO、S、およびNR135から選択され、ここで、R135はHおよびC1-3アルキルから選択され、各uu、uu'、およびuu''は独立して0および1から選択され、Abは抗体またはその断片もしくは誘導体であり、L'は
qは1から20までにわたり、rr、rr'、およびrr''は各々独立して0から8までにわたり、各X40およびX41は独立してO、S、およびNR135から選択され、ここで、R135はHおよびC1-3アルキルから選択され、各uu、uu'、およびuu''は独立して0および1から選択され、Abは抗体またはその断片もしくは誘導体であり、L'は
q*は1から20までにわたり、rr、rr'、およびrr''は各々独立して0から8までにわたり、各X40およびX41は独立してO、S、およびNR135から選択され、ここで、R135はHおよびC1-3アルキルから選択され、各uu、uu'、およびuu''は独立して0および1から選択され、Abは抗体またはその断片もしくは誘導体である。
V1−Z (IIId)
によって表される。
V2−L2−L−Z (IIIe)
によって表される。
式(I)−(IV)の化合物は、WO 01/83448、WO 02/083180、WO 2004/043493, WO 2007/018431、WO 2007/089149およびWO 2009/017394で報告された化合物に幾らか類似した方法で従来通り調製できる。
1つの態様において、本発明は、式(III)の化合物の調製のための式(I)または(II)の化合物の使用に関する。
例1
化合物2および6のアルキル化についての一般的手法
DMF中のNaH(2.5当量)の懸濁液にDMF中のブロモナフタレン2または6の溶液を加え、得られる混合物を1時間室温で撹拌した。アルケン(1.6当量)を加え、混合物をさらに2時間室温で撹拌した。反応を飽和NH4Cl水溶液でゆっくりとクエンチし、得られる混合物をEtOAcで抽出した。有機層を水と食塩水で洗浄し、乾燥(Na2SO4)、ろ過、および濃縮した。粗生成物をカラムクロマトグラフィーを用いて精製するとアルキル化したナフタレン3または7を与えた。
トルエン中のナフタレン3,7,11または15の溶液を、窒素を溶液中に10分間吹き込むことにより窒素雰囲気下にして、AIBN(0.25当量)およびTTMSS(1.1当量)を加えて、混合物を80℃で4時間撹拌した。反応混合物を室温に冷やし、水を加え、得られる混合物をEtOAcで抽出した。有機層を乾燥(Na2SO4)、ろ過、および濃縮した。粗生成物をヘプタンから再結晶させ、さらにカラムクロマトグラフィーで精製すると化合物4,8,12または16をラセミ混合物として与えた。エナンチオマーの分離をキラルHPLC(Chiralpak IA,ヘプタン/DCM)により行った。
化合物4b:1H NMR(300MHz,CDCl3),δ(ppm):1.61(9H,s,Boc),3.42(1H,t,J=10.0Hz,H−10),3.91(1H,d,J=10.0Hz,H−10),4.00−4.10(2H,m,H−1,H−2),4.29(1H,d,J=10.2Hz,H−2),5.26(2H,s,OCH2Ph),7.10−7.55(7H,m,OCH2Ph,H−7,H−8),7.92(1H,bs,H−4),8.06(1H,d,J=8.1Hz,H−6);
化合物4c:1H NMR(300MHz,CDCl3),δ(ppm):1.61(9H,s,Boc),3.50(1H,dd,J=9.2Hz,11.2Hz,H−10),3.97(1H,dd,J=2.8Hz,11.2Hz,H−10),4.08(1H,dd,J=8.4Hz,11.8Hz,H−2),4.34(1H,d,J=11.8Hz,H−2),4.55−4.65(1H,m,H−1),5.27(2H,s,OCH2Ph),7.33(1H,dd,J=7.2Hz,8.4Hz,H−7),7.35−7.55(5H,m,OCH2Ph),7.91(1H,dd,J=1.3Hz,7.2Hz,H−6),8.00(1H,bs,H−4),8.55(1H,dd,J=1.3Hz,8.4Hz,H−6);
化合物4d:1H NMR(300MHz,CDCl3),δ(ppm):1.29(3H,t,J=7.2Hz,9−CH3),1.61(9H,s,Boc),2.96(1H,m,9−CH2),3.19(1H,m,9−CH2),3.23(1H,t,J=10.6Hz,H−2a),3.60(1H,m,H−2b),3.99(2H,m,H−10),4.30(1H,d,J=10.6Hz,H−1),5.26(2H,s,OCH2Ph),7.23−7.45(7H,m,7−H,8−H,OCH2Ph),7.91(1H,bs,H−4),8.25(1H,m,H−6);
化合物4e:1H NMR(300MHz,CDCl3),δ(ppm):1.64−1.57(12H,m,C(CH3)3,10−CH3),3.88−4.00(4H,m,9−OCH3,H−2a),4.17(1H,dt,J=9.3,2.3Hz,H−1),4.28(1H,bs,J=9.6Hz,H−2b),4.53(1H,dq,J=7.1,1.9Hz,H−10),5.25(2H,s,OCH2Ph),6.81(1H,d,J=7.7Hz,H−8),7.20(1H,t,J=8.1Hz,H−7),7.30−7.60(5H,m,OCH2Ph),7.91(1H,d,J=8.6Hz,H−6),7.96(1H,bs,H−4);
化合物4f:1H NMR(300MHz,CDCl3),δ(ppm):1.57(3H,t,CH2CH3),1.60(9H,s,(CH3)3),3.30(1H,dd),3.97(2H,m),4.16(2H,dd,J=1.5Hz,7.2Hz),4.28(2H,q,CH2CH3),5.25(2H,s,OCH2Ph),6.82(1H,d,J=7.5Hz,H−8),7.20(1H,dd,J=7.8Hz,8.4Hz,H−7),7.37−7.54(3&2H,2×m,OCH2Ph),7.87(1H,d,J=8.4Hz,H−6),7.89(1H,bs,H−4);MS(ESI)m/z=468[M+H]+;
化合物4g:1H NMR(300MHz,CDCl3),δ(ppm):1.12(3H,OCH2CH2CH3),1.60(9H,s,(CH3)3),1.98(2H,m,OCH2CH2CH3),3.29(1H,dd),3.97(3H,m),4.06(1H,m),4.29(2H,m),5.24(2H,s,OCH2Ph),6.81(1H,d,J=7.8Hz,H−8),7.19(1H,J=7.8Hz,8.4Hz,H−7),7.33−7.54(3&2H,2×m,OCH2Ph),7.87(1H,d,J=8.4Hz,H−6),7.89(1H,bs,H−4);
化合物4h:1H NMR(300MHz,CDCl3),δ(ppm):1.49(6H,dd,J=5.7Hz,10.8Hz,2×CH3),1.60(9H,s,Boc),3.29(1H,t,J=10.5Hz,H−10a),3.91−4.02(2H,m,H−1,H−10b),4.22−4.36(2H,m,H−2a,H−2b),4.74−4.82(1H,m,OCH),5.25(2H,s,OCH2Ph),6.83(1H,d,J=7.5Hz,H−8),7.16−7.58(6H,m,H−7,OCH2Ph),7.82−7.91(2H,m,H−6,H−4);
化合物4i:1H NMR(300MHz,CDCl3),δ(ppm):1.61(9H,s,(CH3)3),3.31(1H,t),3.99(2H,m),4.31(1H,d),4.60(1H,m),5.25(2H,s,OCH2Ph),7.19(1H,dd),7.39−7.55(6H,m),7.96(1H,bs,H−4),8.25(1H,d);
化合物4j:1H NMR(300MHz,CDCl3),δ(ppm):1.60(9H,s,(CH3)3),3.31(1H,dd,J=10.2Hz),3.90−4.00(2H,m),3.96(3H,s,OCH3),4.25(2H,m),5.24(2H,s,OCH2Ph),6.83(1H,d,J=7.5Hz,H−8),7.20(1H,dd,J=7.8Hz,8.4Hz,H−7),7.34−7.54(3&2H,2×m,OCH2Ph),7.87(1H,d,H−6),7.89(1H,bs,H−4);
化合物4k:1H NMR(400MHz,CDCl3),δ(ppm):1.56−1.61(12H,m,Boc,10−CH3),2.69(3H,s,9−CH3),3.99−4.08(2H,m,H−2,H−10),4.18−4.3(2H,m,H−2,H−1),5.26(2H,bs,OCH2Ph),7.18−7.28(2H,m,Ar−H),7.34−7.44(3H,m,Ar−H),7.54(2H,d,J=6.5Hz,Ar−H),7.97(1H,bs,H−4),8.23(1H,d,J=7.8Hz,H−8);MS(ESI)m/z=396[M+H]+;
化合物8a:1H NMR(300MHz,CDCl3),δ(ppm):1.60(9H,s,Boc),3.28−3.44(3H,m,ジヒドロフラン+H−2),3.96−4.18(3H,m,H−2,H−1,H−10),4.22−4.32(1H,m,H−10),4.73(2H,dt,J=1.8,9.0Hz,ジヒドロフラン),5.24(2H,s,OCH2Ph),7.18(1H,d,J=8.4Hz,H−7),7.30−7.55(5H,m,OCH2Ph),7.81(1H,bs,H−4),7.81(1H,d,J=8.4Hz,H−6);
化合物8b:1H NMR(400MHz,CDCl3),δ(ppm):1.55−1.66(12H,m,Boc+10−Me),3.26−3.42(2H,m,ジヒドロフラン),3.92−4.02(2H,m,H−2),4.22−4.34(1H,m,H−1),4.60−4.72(3H,m,ジヒドロフラン+H−10),5.25(2H,s,OCH2Ph),7.17(1H,d,J=8.4Hz,H−7),7.32−7.58(5H,m,OCH2Ph),7.83(1H,bs,H−4),7.84(1H,d,J=8.4Hz,H−6);
化合物8c:1H NMR(300MHz,CDCl3),δ(ppm):1.60(9H,s,Boc),3.38−3.47(1H,m,H−2),3.94−4.11(3H,m,H−2,H−1,H−10),4.22−4.31(1H,m,H−10),5.24(2H,s,OCH2Ph),6.09(1H,d,J=1.5Hz,ジオキシメチレン),6.15(1H,d,J=1.5Hz,ジオキシメチレン),7.00(1H,d,J=8.9Hz,H−7),7.32−7.56(5H,m,OCH2Ph),7.70(1H,bs,H−4),7.87(1H,d,J=8.9Hz,H−6);
化合物8d:1H NMR(400MHz,CDCl3),δ(ppm):1.56−1.64(12H,m,Boc+10−Me),3.85−3.90(1H,m,H−2),3.96−4.04(1H,m,H−2),4.23−4.33(1H,m,H−1),4.58−4.66(1H,m,H−10),5.24(2H,s,OCH2Ph),6.07(1H,d,J=1.3Hz,ジオキシメチレン),6.12(1H,d,J=1.3Hz,ジオキシメチレン),7.00(1H,d,J=8.9Hz,H−7),7.32−7.56(5H,m,OCH2Ph),7.75(1H,bs,H−4),7.89(1H,d,J=8.9Hz,H−6);
化合物12:1H NMR(300MHz,CDCl3),δ(ppm):1.60(9H,s,Boc),3.32(1H,t,J=10.2Hz,H−10),3.86−4.01(2H,m,H1,H−10),3.99(3H,s,OMe),4.18−4.30(3H,m,H−2,H−Fmoc),4.53(2H,d,J=6.8Hz,H−Fmoc),5.21(2H,s,OCH2Ph),6.82(1H,bs,NH),7.28−7.55(11H,m,OCH2Ph,H−Fmoc),7.61(1H,s,H−8),7.64(1H,s,H−6),7.90(1H,bs,H−4);
化合物16:1H NMR(300MHz,CDCl3),δ(ppm):1.61(9H,s,Boc),3.26(1H,t,J=9.9Hz,H−10a),3.77(3H,s,OMe),3.86−3.99(2H,m,H−10b,H−2a),4.06−4.13(1H,m,H−1),4.24−4.34(2H,m,H−2b,H−Fmoc),4.60(2H,d,J=6.9H,H−Fmoc),5.25(2H,s,OCH2Ph),7.26−7.45(8H,m),7.50−7.54(2H,d),7.64(2H,d),7.78(2H,d),8.04−8.10(2H,m)。
N−Boc−O−Bn−保護した seco CBI誘導体を4M HCl/ジオキサンに溶かし、周囲温度でTLCが反応の完了を示すまで撹拌した。反応混合物を真空中で濃縮し、さらに高真空下で乾燥させた。残渣を乾燥DMFに溶かし、溶液を0℃に冷やし、EDC(2.0当量)と、官能性をもたせ任意にBoc保護したインドール−2−カルボキシラート(1.5当量)を加えた。反応混合物を周囲温度に終夜昇温させて、その後真空中で濃縮した。残渣を水/EtOAcに溶解させ、飽和NaHCO3水溶液を加えて、混合物をEtOAcで抽出した。集めた有機層を食塩水で洗浄し、乾燥(Na2SO4)、ろ過し、真空中で濃縮した。フラッシュクロマトグラフィーによりベンジル保護された物質を得た。この化合物をメタノールに溶かして、Pd/C(10%Pd,0.2当量)とHCOONH4(10当量)を加えた。反応混合物を40℃でTLCが反応の完了を示すまで撹拌した。反応混合物を室温に冷やし、セライト床上でろ過した。セライトをMeOHで十分にすすいで、集めたろ液を真空中で濃縮した。フラッシュクロマトグラフィーにより純粋な物質で、任意にBoc基によりなお保護されたものを得た。このBoc基の除去を、化合物をジオキサン中4M HClに溶解させることにより行った。混合物をTCLが反応の完了を示すまで撹拌した。反応混合物を濃縮すると純粋な化合物を与えた。
化合物18:1H NMR(300MHz,DMSO−d6),δ(ppm):3.44−3.50(4H,m,H−2'',H−3''),3.62(1H,dd,J=8.1Hz,10.4Hz,H−10),3.88(2H,t,J=5.0Hz,H−4''),3.88−3.98(4H,m,H−10,OMe),3.93−4.00(4H,m,H−10,OMe),4.27−4.37(1H,m,H−1),4.54(d,J=10.4Hz,H−2),4.60−4.75(3H,m,H−1'',H−2),7.00(1H,d,J=7.8Hz,H−8),7.17(1H,d,J=1.3Hz,H−3'),7.28(1H,dd,J=7.8Hz,8.2Hz,H−7),7.45(1H,d,J=8.9Hz,H−7'),7.64(1H,dd,J=1.9Hz,8.9Hz,H−6'),7.71(1H,d,J=8.2Hz,H−6),8.00(1H,s,H−4),8.21(1H,d,J=1,5Hz,H−4'),8.69(1H,s,トリアゾリル−H),10.32(1H,s,NH),10.40(1H,s,OH),11.70(1H,s,NH),MS(ESI)m/z=605[M+H]+;
化合物19:1H NMR(300MHz,CDCl3),δ(ppm):3.5(12H,m),3.9(3H,t,J=4.2Hz),4.0(3H,s,9−OCH3),4.3(1H,t,J=7.6Hz,H−2a),4.5(1H,d,J=11.0Hz,H−2b),4.6(4H,t,J=4.8Hz),6.6(2H,d,J=8.2Hz),7.0(1H,d,J=8.2Hz,H−8),7.2(1H,s,H−3'),7.3(1H,t,J=7.6Hz,H−7),7.5(1H,d,J=9.0Hz,H−6'),7.6(2H,d,J=8.5Hz),7.6(1H,d,J=9.0Hz),7.7(1H,d,J=8.2Hz,H−6),8.0(2H,s,CH),8.2(1H,s,H−4),8.7(1H,s,H−4'),10.3(1H,s,NH),10.4(1H,s,NH),11.7(1H,s,NH);MS(ESI)m/z=811.3[M+H]+;
化合物20:1H NMR(300MHz,DMSO−d6),δ(ppm):2.94(2H,六重線,CH2NH3),3.48−3.66(15H,m,CH2),3.89(2H,t,CH2),3.92−4.03(4H,m),4.33(1H,t,J=7.5Hz),4.53(1H,d,J=11Hz),4.65(2H,t,J=4.6Hz),4.72(1H,d,J=15Hz),7.0(1H,d,J=7.5Hz),7.18(1H,s),7.28(1H,t,J=8.1Hz),7.46(1H,d,J=8Hz),7.64(1H,d,J=9.9Hz),7.71(1H,d,J=9.3Hz),7.93(3H,s),8.00(1H,s),8.2(1H,s),8.7(1H,s),10.3(1H,s),10.4(1H,s),11.7(1H,s);
化合物21:1H NMR(300MHz,CD3OD),δ(ppm):3.48−3.64(13H,m),3.95(2H,m,(C=O)−CH2),4.00(4H,m,OCH3,H−10),4.40(1H,m,H−1),4.68(5H,m,H−2+(C=O)CH2CH2),6.97(1H,d,J=7.3Hz),7.17(1H,s),7.28(1H,t,J=7.9Hz),7.53(2H,m),7.80(1H,d,J=8.2Hz),7.84(1H,m),8.13(1H,s),8.55(1H,s);MS(ESI)m/z=707.3[M+H]+,729.3[M+Na]+。
化合物37:1H NMR(300MHz,DMSO),δ(ppm):2.75(3H,s,9−Me),3.51(1H,t,J=10.5Hz,H−10),3.77(1H,d,J=10.8Hz,H−10),4.06(1H,d,J=9.9Hz,H−2),4.16(1H,t,J=10.5Hz,H−2),4.33−4.39(1H,m,H−1),6.77(2H,d,J=9.0Hz,H−2''),7.21(1H,t,J=7.2Hz,H−7),7.32(1H,d,J=6.6Hz,H−8),7.44−7.61(6H,m,H−4,H−3',H−6',H−7',H−1''),8.00−8.04(2H,m,H−6,H−4'),9.27(1H,s,OH),10.11(1H,s,NH),10.36(1H,s,OH),11.99(1H,s,NH);MS(ESI)m/z=526.3[M+H]+;
化合物38:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.47−3.56(5H,m,H−10),3.73−3.79(3H,m,H−10),4.03−4.10(3H,m,H−2),4.16(1H,t,J=7.8Hz,H−2),4.33−4.39(1H,m,H−1),4.62(1H,m,OH),6.97(2H,d,J=9.0Hz,H−2''),7.23(1H,t,J=7.8Hz,H−7),7.32(1H,d,J=6.9Hz,H−8),7.49−7.58(4H,m,H−4,H−3',H−6',H−7'),7.72(2H,d,J=9.0Hz,H−1''),8.00−8.05(2H,m,H−6,H−4'),10.23(1H,s,NH),10.36(1H,s,OH),12.04(1H,s,NH);MS(ESI)m/z=614.5[M+H]+;
化合物39:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.39−3.58(13H,m,H−10),3.73−3.79(3H,m,H−10),4.04−4.10(3H,m,H−2),4.16(1H,t,J=9.0Hz,H−2),4.33−4.39(1H,m,H−1),4.57(1H,t,J=5.4Hz,OH),6.98(2H,d,J=9.0Hz,H−2''),7.22(1H,t,J=7.2Hz,H−7),7.31(1H,d,J=6.9Hz,H−8),7.48−7.58(4H,m,H−4,H−3',H−6',H−7'),7.71(2H,d,J=9.0Hz,H−1''),8.00−8.05(2H,m,H−6,H−4'),10.22(1H,s,NH),10.36(1H,s,OH),12.03(1H,s,NH);MS(ESI)m/z=724.5[M+H]+;
化合物42:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.24(3H,s,OMe),3.40−3.61(13H,m,H−10),3.73−3.80(3H,m,H−10),4.04−4.10(3H,m,H−2),4.17(1H,t,J=7.8Hz,H−2),4.34−4.40(1H,m,H−1),6.97(2H,d,J=9.0Hz,H−2''),7.21(1H,t,J=6.6Hz,H−7),7.32(1H,d,J=6.6Hz,H−8),7.49−7.58(4H,m,H−4,H−3',H−6',H−7'),7.71(2H,d,J=9.0Hz,H−1''),8.00−8.05(2H,m,H−6,H−4'),10.21(1H,s,NH),10.37(1H,s,OH),12.02(1H,s,NH);MS(ESI)m/z=738.5[M+H]+;
化合物43:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.51(1H,m,H−10),3.78(1H,m,H−10),4.6(1H,d,J=10.5Hz,H−2),4.17(1H,t,J=8.1Hz,H−2),4.34−4.37(1H,m,H−1),6.72(1H,m,H−4''),7.12−7.79(9H,m,H−7,H−8,H−4,H−3',H−6',H−7',H−2'',H−3'',H−6''),8.00−8.05(2H,m,H−6,H−4'),10.39(2H,s,NH,OH),12.12(1H,s,NH);MS(ESI)m/z=525.6[M+H]+;
化合物44:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.39−3.62(13H,m,H−10),3.75−3.79(3H,m,H−10),4.04−4.21(4H,m,H−2,H−2),4.33−4.37(1H,m,H−1),4.55(1H,bs,OH),6.72(1H,m,H−4''),7.20−7.33(3H,m,H−7,H−8,H−3''),7.41(1H,d,J=8.1Hz,H−2''),7.50−7.59(5H,m,H−4,H−3',H−6',H−7',H−6''),8.00−8.06(2H,m,H−6,H−4'),10.26(1H,s,NH),10.37(1H,s,OH),12.05(1H,s,NH);MS(ESI)m/z=702.7[M+H]+;
化合物45:1H NMR(300MHz,DMSO),δ(ppm):2.75(3H,s,9−Me),3.51(1H,t,J=10.2Hz,H−10),3.77(1H,d,J=10.2Hz,H−10),4.04(1H,m,H−2),4.18(1H,m,H−2),4.34−4.39(1H,m,H−1),7.04(2H,m,NH2),7.17−7.24(3H,m,H−7,H−2''),7.30−7.35(3H,m,H−8,H−4',H−5'),7.51−7.54(3H,m,H−3',H−1''),7.30−7.80(2H,m,4−H,H−7'),8.01(1H,d,J=8.4Hz,H−6),10.41(2H,m,OH,NH),12.14(1H,s,NH);MS(ESI)m/z=525.3[M+H]+;
化合物46:1H NMR(300MHz,DMSO),δ(ppm):2.75(3H,s,9−Me),3.37−3.59(17H,m,H−10),3.73(1H,d,J=10.2Hz,H−10),4.04(1H,d,J=11.1Hz,H−2),4.16(1H,t,J=7.8Hz,H−2),4.32−4.38(1H,m,H−1),4.56(1H,t,J=5.4Hz,OH),7.19−7.26(2H,m,H−7,H−3'),7.31(1H,d,J=7.2Hz,H−8),7.46−7.54(3H,m,H−4,H−6',H−7'),7.98−8.03(2H,m,H−6,H−4'),8.64(1H,t,J=5.7Hz,NH),10.35(1H,s,OH),11.88(1H,s,NH);MS(ESI)m/z=610.5[M+H]+。
化合物48:1H NMR(300MHz,DMSO),δ(ppm):2.75(3H,s,9−Me),3.48(1H,t,J=10.2Hz,H−10),3.77(1H,d,J=10.2Hz,H−10),4.08(1H,d,J=10.5Hz,H−2),4.17(1H,t,J=8.1Hz,H−2),4.34−4.39(1H,m,H−1),6.81(1H,s,H−3'),6.87(2H,d,J=8.7Hz,H−2''),7.20(1H,t,J=6.9Hz,H−7),7.30−7.37(2H,m,H−8,H−7'),7.45(1H,d,J=8.4Hz,H−6'),7.55(1H,bs,H−4),7.71(2H,d,J=8.7Hz,H−1''),7.82(1−H,s,H−4'),8.01(1H,d,J=8.4Hz,H−6),9.69(1H,s,OH),10.35(1H,s,OH),11.66(1H,s,NH);MS(ESI)m/z=483.4[M+H]+;
化合物49:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.50(1H,t,J=9.6Hz,H−10),3.77(1H,d,J=11.1Hz,H−10),4.08(1H,d,J=11.1Hz,H−2),4.17(1H,t,J=7.8Hz,H−2),4.31−4.37(1H,m,H−1),6.81(1H,s,H−3'),6.88(2H,d,J=8.7Hz,H−2''),7.20(1H,t,J=7.2Hz,H−7),7.21−7.32(2H,m,H−8,H−4'),7.51−7.59(2H,m,H−4,H−5'),7.65(1H,s,H−7'),7.72(2H,d,J=8.7Hz,H−1''),8.01(1H,d,J=8.4Hz,H−6),9.71(1H,s,OH),10.35(1H,s,OH),11.65(1H,s,NH);MS(ESI)m/z=483.4[M+H]+;
化合物50:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),2.86(6H,s,N−(CH3)2),3.51(1H,m,H−10,NCH2),3.77(1H,m,H−10),4.07(1H,m,H−2),4.16(1H,m,H−2),4.34−4.42(3H,m,H−1,OCH2),6.81(1H,m,H−3'),6.87(2H,m,H−2''),7.20(1H,m,H−7),7.30−7.37(2H,m,H−8,H−7'),7.45(1H,m,H−6'),7.55(1H,bs,H−4),7.86(3H,m,H−4',H−1''),8.01(1H,m,H−6),10.35(1H,s,OH),11.80(1H,s,NH);MS(ESI)m/z=554.5[M+H]+;
化合物51:1H NMR(300MHz,DMSO−D6),δ(ppm):2.72(3H,s,9−Me),2.81(6H,s,N(CH3)2),3.17(2H,m,NCH2),3.78(1H,d,H−10),4.05(1H,d,H−2),4.16(1H,t,H−2),4.32(1H,t,H−1),4.39(2H,t,OCH2),6.89(1H,s),7.12(2H,d),7.20(1H,t),7.28(2H,t),7.58(2H,d),7.67(1H,s),7.88(2H,d),8.00(1H,d,J=8.2Hz,H−6),10.36(1H,s,OH),11.88(1H,s,NH);MS(ESI)m/z=554.7[M+H]+;
化合物52:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.47−3.56(4H,m,H−10),3.76−3.81(3H,m,H−10),4.07(1H,d,J=10.8Hz,H−2),4.14−4.20(3H,m,H−2),4.34−4.36(1H,m,H−1),4.62−4.66(1H,m,OH),6.91−6.95(1H,m,H−4''),7.06(1H,s,H−3'),7.21(1H,t,J=6.9Hz,H−7),7.31(1H,d,J=6.6Hz,H−8),7.36−7.42(2H,m,H−6',H−6''),7.47−7.58(4H,m,H−4,H−7',H−2'',H−3''),7.88(1H,s,H−4'),8.02(1H,d,J=8.1Hz,H−6),10.35(1H,s,OH),11.83(1H,s,NH);MS(ESI)m/z=571.5[M+H]+;
化合物53:1H NMR(300MHz,DMSO−D6),δ(ppm):2.73(3H,s,9−Me),3.49(4H,m,2CH2),3.78(3H,CH2),4.11(4H,m,CH2),4.31(1H,dd),4.59(1H,t),6.87(1H,s),7.04(2H,d),7.17(1H,t),7.28(2H,t),7.58(2H,d),7.64(1H,s),7.81(2H,d),8.00(1H,d,J=7.7Hz,H−6),10.33(1H,s,OH),11.70(1H,s,NH);MS(ESI)m/z=571.7[M+H]+;
化合物54:1H NMR(300MHz,DMSO−D6),δ(ppm):2.73(3H,s,9−Me),3.76(2H,m),4.07(1H,dd),4.13(1H,t),4.32(1H,t),6.74(3H,m),7.18(1H,t),7.29(3H,m),7.39(1H,m),7.59(2H,d),7.77(1H,s),7.99(1H,d,J=7.9Hz,H−6),10.31(1H,s,OH),11.55(1H,s,NH);MS(ESI)m/z=482.6[M+H]+;
化合物55:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.46−3.53(1H,m,H−10),3.76−3.79(1H,m,H−10),4.09−4.20(2H,m,2×H−2),4.32−4.37(1H,m,H−1),6.77−8.82(3H,m,H−3',H−2''),7.21−7.33(3H,H−7,H−8,H−4'),7.51−7.59(2H,m,H−4,H−5'),7.63−7.67(3H,m,H−7',H−1''),8.02(1H,d,J=8.4Hz,H−6),10.35(1H,s,OH),11.59(1H,s,NH);MS(ESI)m/z=482.5[M+H]+;
化合物56:1H NMR(300MHz,DMSO−D6),δ(ppm):2.73(3H,s,9−Me),3.73(2H,m),4.04(1H,m),4.14(1H,t),4.34(1H,t),6.73(1H,m),6.87(1H,s),7.23(6H,m),7.37(1H,d,J=8.22Hz),7.46(2H,d,J=8.37Hz),7.86(1H,s),7.99(1H,d,J=8.1Hz,H−6),10.33(1H,s,OH),11.76(1H,s,NH);MS(ESI)m/z=482.6[M+H]+;
化合物57:1H NMR(300MHz,DMSO),δ(ppm):2.76(3H,s,9−Me),3.47−3.53(1H,m,H−10),3.77−3.81(1H,m,H−10),4.10(1H,d,J=10.8Hz,H−2),4.18(1H,t,J=7.5Hz,H−2),4.31−4.35(1H,m,H−1),6.75(1H,m,H−4''),6.87(1H,s,H−3'),7.19−7.33(5H,m,H−7,H−8,H−5',H−2'',H−3''),7.51−7.68(3H,m,H−4,H−4',H−6'),8.02(1H,d,J=7.5Hz,H−6),10.36(1H,s,OH),11.76(1H,s,NH);MS(ESI)m/z=482.6[M+H]+;
化合物103:1H NMR(300MHz,DMSO−d6),δ(ppm):2.75(3H,s,9−Me),3.49(1H,m,H−10),3.75(1H,m,H−10),3.82(3H,s,MeO),4.08(1H,d,J=10.9Hz,H−2),4.16(1H,m,H−2),4.35(1H,m,H−1),6.89(1H,s,H−3'),7.06(2H,d,J=8.6Hz,H−3''),7.21(1H,t,J=7.6Hz,H−7),7.31(1H,d,J=6.8Hz,H−8),7.37(1H,d,J=8.4Hz,H−6'),7.47(1H,d,J=8.4Hz,H−7'),7.55(1H,bs,H−4),7.83(2H,d,J=8.6Hz,H−3''),8.02(1H,d,J=7.7Hz,H−6),10.34(1H,bs,OH),11.73(1H,s,NH);MS(ESI)m/z=497[M+H]+。
化合物68:1H NMR(300MHz,DMSO−d6),δ(ppm):2.15(2H,m,OCH2CH2),2.76(3H,s,9−Me),2.84(6H,d,J=4.8Hz,NMe),3.25(2H,m,NCH2CH2),3.55(1H,t,J=11.0Hz,H−10),3.77(1H,d,J=11.0Hz,H−10),4.04(1H,d,J=11Hz,H−2),4.13−4.22(3H,m,H−1,OCH2),4.34(1H,m,H−2),7.18(2H,d,J=9.1Hz,H−3''),7.22(1H,t,J=6.9Hz,H−7),7.33(1H,d,J=6.6Hz,H−8),7.54(1H,dd,J=8.5Hz,J=0.5Hz,H−6'),7.60(1H,bs,H−4),7.72(1H,d,J=8.1Hz,H−7'),7.90(1H,s,H−4'),8.02(1H,d,J=8.4Hz,H−6),8.19(2H,d,J=9.3Hz,H−2''),9.45(1H,s,OH),10.38(1H,s,NH);MS(ESI)m/z=569[M+H]+;
化合物69:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.51(5H,m,2×O−CH2,H−10a),3.78(3H,m,O−CH2,H−10b),4.06(1H,d,J=10.8Hz,H−1),4.22(3H,m,O−CH2,H−2a),4.33(1H,m,H−2b),4.63(1H,m,OH),7.10(2H,d,J=8.9Hz,2×CH),7.21(1H,t,J=8.2Hz,H−7'),7.32(1H,d,J=7.0Hz,H−8'),7.44(1H,d,J=8.9Hz,CH),7.57(1H,m,CH),7.77(1H,s,H−4'),8.01(1H,d,J=8.2Hz,H−6'),8.14(2H,d,J=8.9Hz,2×CH),10.40(1H,s,OH),12.01(1H,bs),12.53(1H,bs);MS(ESI)m/z=615.6[M+H]+;
化合物70:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.51−3.60(5H,m,2×OCH2,H−10a),3.74−3.85(3H,m,OCH2,H−10b),4.06(1H,m,H−1),4.14−4.25(3H,m,OCH2,H−2a),4.35(1H,m,H−2b),4.65(1H,m,OH),7.11(1H,d,J=9.1Hz,CH),7.22(1H,t,J=8.1Hz,H−7'),7.33(1H,d,J=7.1Hz,H−8'),7.50(3H,m,3×CH),7.65(1H,d,J=8.1Hz),7.80(3H,m,3×CH),8.00(2H,m,H−4',H−6'),10.36(1H,s,OH),13.18(1H,s,NH);MS(ESI)m/z=572.5[M+H]+;
化合物82:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.35−3.65(13H,m,6×CH2O,H−10),3.73−3.85(3H,m,H−10,CH2O),4.06(1H,m,H−2),4.13−4.25(3H,m,H−2,CH2O),4.35(1H,m,H−1),4.57(1H,t,J=5.4Hz,OH),7.12(1H,d,J=8.2Hz,H−4''),7.22(1H,t,J=7.7Hz,H−7),7.32(1H,d,J=6.8Hz,H−8),7.40−8.00(7H,m,H−4,H−4',H−5',H−6',H−2'',H−5'',H−6''),8.02(1H,d,J=7.9,H−6),10.36(1H,s,OH),12.17(1H,s,NH);MS(ESI)m/z=660[M+H]+;
化合物83:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.37−3.65(13H,m,6×CH2O,H−10),3.73−3.83(3H,m,H−10,CH2O),4.07(1H,m,H−2),4.12−4.26(3H,m,H−2,CH2O),4.35(1H,m,H−1),4.57(1H,t,J=5.4Hz,OH),7.15(2H,d,J=8.8Hz,H−3''),7.22(1H,t,J=7.7Hz,H−7),7.32(1H,d,J=6.9Hz,H−8),7.47(1H,m,H−6' 互変異性体),7.60(1H,bs,H−4),7.61+7.72(1H,d,J=8.3,H−7' 互変異性体),7.76+7.93(1H,s,H−4' 互変異性体),8.02(1H,d,J=8.4,H−6),10.36(1H,s,OH),13.03(1H,s,NH);MS(ESI)m/z=660[M+H]+;
化合物88:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.49(1H,m,H−10),3.78(1H,d,J=10.1Hz,H−10),4.03(1H,m,H−2),4.20(1H,m,H−2),4.34(1H,m,H−1),6.71(2H,d,J=8.6Hz,H−3'''),7.23(1H,t,J=7.5Hz,H−7),7.33(1H,d,J=6.9Hz,H−8),7.50−7.75(3H,m,H−4,H−7',H−5''),7.80−7.98(5H,m,H−6',H−4'',H−6'',H2'''),8.00−8.07(2H,m,H−6,H−4'),8.83(1H,s,H−2''),10.16(1H,s,OH),10.40(1H,bs,NH);MS(ESI)m/z=602[M+H]+;
化合物89:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.56(1H,m,H−10),3.78(1H,d,J=9.2Hz,H−10),4.07(1H,m,H−2),4.18(1H,m,H−2),4.34(1H,m,H−1),6.89(2H,d,J=8.7Hz,H−3'''),7.21(1H,t,J=7.7Hz,H−7),7.32(1H,d,J=6.8Hz,H−8),7.49(1H,m,H−6'),7.60(1H,bs,H−4),7.63+7.74(1H,d,J=8.2Hz,H−7' 互変異性体),7.79+7.95(1H,s,H−4' 互変異性体),7.89(2H,d,J=8.7Hz,H−2'''),7.98(2H,d,J=8.8Hz,H−3''),8.02(1H,d,J=8.2Hz,H−6),8.18(2H,d,J=8.8Hz,H−2''),10.15(1H,s,OH),10.24(1H,s,OH),10.37(1H,bs,NH);MS(ESI)m/z=603(M+H+);
化合物90:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.54(1H,m,H−10),3.78(1H,d,J=10.7Hz,H−10),3.86(3H,s,OMe),4.07(1H,d,J=11.0Hz,H−2),4.18(1H,m,H−2),4.35(1H,m,H−1),7.11(1H,d,J=8.4Hz,H−5''),7.21(1H,dd,J=6.7Hz,8.0Hz,H−7),7.32(1H,d,J=6.7Hz,H−8),7.46(1H,d,J=8.4Hz,H−7'),7.57(1H,bs,H−4),7.60−7.70(2H,m,H−2'',H−6''),7.74(1H,m,H−6'),7.91(1H,bs,H−4'),8.01(1H,d,J=8.0Hz,H−6),9.33(1H,s,OH),10.36(1H,s,OH),12.96(1H,s,NH);MS(ESI)m/z=514[M+H]+;
化合物91:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.46(4H,bs,2×CH2O),3.56(1H,m,H−10),3.77(1H,m,H−10),3.88(2H,t,J=5.2Hz,CH2O),4.08(1H,m,H−2),4.20(1H,m,H−2),4.35(1H,m,H−1),4.64(3H,m,CH2O,OH),7.21(1H,t,J=7.7Hz,H−7),7.33(1H,d,J=6.7Hz,H−8),7.49(1H,m,H−7'),7.60(1H,bs,H−4),7.62+7.74(1H,d,J=7.9Hz,H−6' 互変異性体),7.79+7.96(1H,s,H−4' 互変異性体),8.02(1H,d,J=8.0Hz,H−6),8.05(2H,d,J=8.8,H−2''),8.18(2H,d,J=8.8,H−3''),8.75(1H,s,トリアゾール−H),10.36(1H,s,NH),10.70(1H,s,OH),13.11(1H,bs,NH);MS(ESI)m/z=666[M+H]+;
化合物92:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.55(1H,m,H−10),3.78(1H,m,H−10),3.86(3H,s,OMe),4.07(1H,m,H−2),4.18(1H,m,H−2),4.35(1H,m,H−1),7.14(2H,d,J=8.8Hz,H−3''),7.21(1H,dd,J=6.9Hz,8.2Hz,H−7),7.31(1H,d,J=6.9Hz,H−8),7.46+7.48(1H,d,J=8.2Hz,H−6',互変異性体),7.56(1H,bs,H−4),7.61+7.73(1H,d,J=8.2,H−7',互変異性体),7.76+7.93(1H,s,H−4' 互変異性体),8.02(1H,d,J=8.2Hz,H−6),8.16(2H,d,J=8.8Hz,H−2''),10.36(1H,bs,OH),13.02(1H,s,NH);MS(ESI)m/z=498(M+H+);
化合物93:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.48(1H,m,H−10),3.78(1H,d,J=10.6Hz,H−10),4.01(1H,m,H−2),4.21(1H,m,H−2),4.33(1H,m,H−1),6.68(2H,d,J=8.6Hz,H−3'''),7.23(1H,t,J=7.7Hz,H−7),7.33(1H,d,J=6.7Hz,H−8),7.74(1H,d,J=8.3Hz,H−7'),7.70(1H,bs,H−4),7.79(2H,d,J=8.6Hz,H−2'''),7.89(1H,d,J=8.3Hz,H−6'),8.02(1H,d,J=7.0Hz,H−6),8.04(1H,s,H−4'),8.10(2H,d,J=8.9Hz,H−3''),8.26(2H,d,J=8.9Hz,H−2''),10.25(1H,s,OH),10.41(1H,bs,NH);MS(ESI)m/z=602[M+H]+;
化合物94:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.52(4H,bs,2×CH2O),3.56(1H,m,H−10),3.70−3.81(3H,m,H−10,CH2O),4.06(1H,d,J=10.5Hz,H−2),4.13−4.23(3H,m,H−2,CH2O),4.35(1H,m,H−1),4.60(1H,bs,OH),7.15(2H,d,J=8.8Hz,H−3''),7.22(1H,t,J=8.2Hz,H−7),7.33(1H,d,J=6.9Hz,H−8),7.47(1H,d,J=8.4Hz,H−2''),7.60(1H,bs,H−4),7.65(1H,bs,H−7'),7.85(1H,bs,H−4'),8.02(1H,d,J=8.0Hz,H−6),8.15(2H,d,J=8.8,H−3''),10.36(1H,s,OH);MS(ESI)m/z=572[M+H]+;
化合物95:1H NMR(300MHz,DMSO−d6),δ(ppm):2.75(3H,s,9−Me),3.59(1H,m,H−10),3.77(1H,d,J=10.4Hz,H−10),4.02(1H,m,H−2),4.20(1H,m,H−2),4.34(1H,m,H−1),7.15(1H,d,J=8.0Hz,H−4''),7.23(1H,t,J=7.8Hz,H−7),7.33(1H,d,J=7.0Hz,H−8),7.49(1H,t,J=7.8Hz,H−5''),7.60−7.80(4H,m,H−4,H−7',H−2'',H−6''),7.85(1H,d,J=8.3Hz,H−6'),8.01(1H,s,H−4'),8.02(1H,d,J=8.0Hz,H−6),10.42(1H,s,OH);MS(ESI)m/z=483[M+H]+;
化合物96:1H NMR(300MHz,DMSO−d6),δ(ppm):2.75(3H,s,9−Me),3.54(1H,m,H−10),3.78(1H,d,J=10.9Hz,H−10),3.90(3H,s,OMe),4.07(1H,d,J=10.7Hz,H−2),4.18(1H,m,H−2),4.35(1H,m,H−1),6.94(1H,d,J=8.2Hz,H−5''),7.21(1H,d,J=7.7Hz,H−7),7.32(1H,d,J=6.7Hz,H−8),7.47(1H,d,J=8.9Hz,H−6'),7.55(1H,bs,H−4),7.60−7.70(2H,m,H−6'',H−7'),7.78(1H,s,H−2''),7.84(1H,s,H−4'),8.02(1H,d,J=8.1Hz,H−6),9.61(1H,s,OH),10.36(1H,s,OH),12.97(1H,s,NH);MS(ESI)m/z=514[M+H]+;
化合物97:1H NMR(300MHz,DMSO−d6),δ(ppm):2.75(3H,s,9−Me),3.54(1H,m,H−10),3.77(1H,d,J=9.7Hz,H−10),4.06(1H,d,J=10.9Hz,H−2),4.18(1H,m,H−2),4.35(1H,m,H−1),6.94(2H,d,J=8.7Hz,H−3''),7.21(1H,t,J=7.6Hz,H−7),7.31(1H,d,J=6.7Hz,H−8),7.47(1H,d,J=8.2Hz,H−6'),7.56(1H,bs,H−4),7.65(1H,d,J=8.2,H−7'),7.83(1H,s,H−4'),8.01(1H,d,J=7.9Hz,H−6),8.04(2H,d,J=8.7Hz,H−2''),10.05(1H,s,OH),10.36(1H,s,OH),13.06(1H,bs,NH);MS(ESI)m/z=484[M+H]+。
化合物35:1H NMR(300MHz,DMSO),δ(ppm):2.75(3H,s,9−Me),3.33(3H,s,OMe),3.45−3.55(1H,m,H−10),3.77(1H,m,H−10),4.04(1H,m,H−2),4.17−4.21(1H,m,H−2),4.29−4.36(1H,m,H−1),7.06−7.51(6H,m,H−4,H−7,H−8,H−4',H−6',H−7'),8.01(1H,m,H−6),10.34−10.36(1H,m,OH),11.05−11.14(1H,m,NH);MS(ESI)m/z=422.1[M+H]+。
化合物72:1H NMR(300MHz,DMSO),δ(ppm):2.79(3H,s,9−Me),3.39−3.78(17H,m,H−10,H−10,OH),4.21(2H,t,J=5.1Hz,OCH2),4.31(1H,t,J=11.4Hz,H−2),4.48(1H,d,J=11.1Hz,H−2),4.66(1H,m,H−1),7.10(2H,d,J=9.0Hz,H−2''),7.16(1H,s,H−3'),7.25(1H,t,J=6.9Hz,H−7),7.34(1H,d,J=6.6Hz,H−8),7.90−8.06(4H,m,H−4,H−6,H−1''),8.53(1H,s,H−4'),8.65(1H,s,H−6'),10.26(1H,s,NH),10.47(1H,s,OH),12.27(1H,s,NH);MS(ESI)m/z=703.5[M+H]+;
化合物73:1H NMR(300MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.22(3H,s,OMe),3.39−3.65(13H,m,6×CH2,H−10a),3.81(3H,m,OCH2,H−10b),4.20(2H,m,OCH2),4.31(1H,m,H−2a),4.49(1H,d,J=10.8Hz,H−1),4.66(1H,m,H−2b),6.92(1H,d,J=8.3Hz,CH),7.16(1H,d,J=2.2Hz,CH),7.24(1H,t,J=6.9Hz,H−7'),7.35(1H,m,H−8'),7.55(1H,d,J=8.3Hz,CH),7.61(1H,m,CH),7.91(1H,s,H−4'),8.05(1H,d,J=7.5Hz,H−6'),8.44(1H,d,J=2.2Hz,CH),8.62(1H,d,J=2.2Hz,CH),9.69(1H,s,NH),10.12(1H,s,OH),10.47(1H,s,OH),12.25(1H,s,NH);MS(ESI)m/z=733.5[M+H]+;
化合物74:1H NMR(300MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.24(3H,s,OMe),3.40−3.64(13H,m,6×CH2,H−10a),3.79(3H,m,OCH2,H−10b),4.19(2H,m,OCH2),4.31(1H,m,H−2a),4.49(1H,d,J=10.9Hz,H−1),4.66(1H,m,H−2b),7.07(1H,d,J=8.2Hz,CH),7.16(1H,m,CH),7.25(1H,t,J=7.2Hz,H−7'),7.35(1H,d,J=7.0Hz,H−8'),7.50(2H,m,CH),7.93(1H,bs,H−4'),8.05(1H,d,J=8.2Hz,H−6'),8.51(1H,d,J=2.3Hz,CH),8.63(1H,d,J=2.3Hz,CH),9.28(1H,s,NH),10.18(1H,s,OH),10.47(1H,s,OH),12.24(1H,s,NH);MS(ESI)m/z=733.5[M+H]+;
化合物75:1H NMR(300MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.53(5H,m,2×OCH2,H−10a),3.79(3H,m,OCH2,H−10b),4.21(2H,m,OCH2),4.31(1H,m,H−2a),4.49(1H,d,J=10.6Hz,H−1),4.63(2H,m,OH,H−2b),7.18(1H,s,CH),7.20(1H,m,CH),7.25(1H,t,J=7.2Hz,H−7'),7.35(1H,d,J=6.9Hz,H−8'),7.47(1H,t,J=8.1Hz,CH),7.59(2H,m,2×CH),7.94(1H,s,H−4'),8.05(1H,d,J=8.1Hz,H−6'),8.54(1H,d,J=2.4Hz,CH),8.66(1H,d,J=2.4Hz,CH),10.37(1H,s,NH),10.47(1H,s,OH),12.28(1H,s,NH);MS(ESI)m/z=615.5[M+H]+;
化合物76:1H NMR(300MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.51(1H,t,J=10.7Hz,H−10),3.80(1H,d,J=11.3Hz,H−10),4.31(1H,t,J=8.7Hz,H−1),4.49(1H,d,J=10.5Hz,H−2),4.66(1H,dd,J=10.5Hz,10.0Hz,H−2),5.76(2H,s,NH2),6.62(2H,d,J=8.7Hz,H−3''),7.15(1H,d,J=2.18Hz,H−3'),7.25(1H,dd,J=8.7Hz,7.0Hz,H−7),7.35(1H,d,J=7.0Hz,H−8),7.77(2H,d,J=8.6Hz,H−2''),7.93(1H,s,H−4),8.04(1H,d,J=8.2Hz,H−6),8.50(1H,d,J=2.2Hz,H−4'),8.63(1H,d,J=2.4Hz,H−6'),9.92(1H,s,OH),10.47(1H,s,NH),12.20(1H,s,NH);MS(ESI)m/z=526[M+H]+;
化合物77:1H NMR(300MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.47−3.58(5H,m,CH2,H−10),3.75−3.85(3H,m,CH2,H−10),4.20(2H,m,CH2),4.31(1H,t,J=7.5Hz,H−1),4.49(1H,d,J=10.9Hz,H−2),4.60−4.71(2H,m,H−2,OH),7.10(2H,d,J=9.5Hz,H−3''),7.17(1H,d,J=2.0Hz,H−3'),7.25(1H,dd,J=7.1Hz,8.5Hz,H−7),7.35(1H,d,J=7.1Hz,H−8),7.94(1H,s,H−4),8.00(2H,d,J=8.9Hz,H−2''),8.05(1H,d,J=8.3Hz,H−6),8.53(1H,d,J=2.3Hz,H−4'),8.65(1H,d,J=2.4Hz,H−6'),10.25(1H,s,NH),10.47(1H,s,OH),12.26(1H,s,NH);MS(ESI)m/z=615[M+H]+。
化合物59:1H NMR(300MHz,DMSO),δ(ppm):2.79(3H,s,9−Me),3.58(1H,m,H−10),3.79(1H,m,H−10),4.34(1H,m,H−2),4.47(1H,m,H−2),4.67(1H,m,H−1),6.93(2H,d,J=8.7Hz,H−2''),7.27(1H,t,J=7.2Hz,H−7),7.35−7.42(1H,m,H−8,H−3'),7.98−8.08(4H,m,H−4,H−6,H−1''),8.41(1H,s,H−4'),8.86(1H,s,H−7'),10.16(1H,s,OH),10.56(1H,s,OH),11.15(1H,s,NH),12.80(1H,s,NH);MS(ESI)m/z=527.4[M+H]+;
化合物60:1H NMR(300MHz,DMSO),δ(ppm):2.80(3H,s,9−Me),3.39−3.62(14H,m,H−10,OH),3.77(3H,m,H−10),4.23(2H,t,J=4.2Hz),4.36(1H,t,J=6.9Hz,H−2),4.49(1H,d,J=10.8Hz,H−2),4.70(1H,m,H−1),7.12(2H,d,J=8.7Hz,H−2''),7.27(1H,t,J=7.2Hz,H−7),7.35−7.42(2H,m,H−8,H−3'),7.97−8.13(4H,m,H−4,H−6,H−1''),8.38(1H,s,H−4'),8.86(1H,s,H−7'),10.54(1H,s,OH),11.20(1H,s,NH),12.78(1H,s,NH);MS(ESI)m/z=703.5[M+H]+;
化合物61:1H NMR(300MHz,DMSO),δ(ppm):2.79(3H,s,9−Me),3.24(3H,s,OMe),3.40−3.62(13H,m,H−10),3.76−3.82(3H,m,H−10),4.19(2H,t,J=4.5Hz),4.34(1H,t,J=7.5Hz,H−2),4.53(1H,d,J=12.0Hz,H−2),4.70(1H,m,H−1),7.06(2H,d,J=8.7Hz,H−2''),7.23−7.28(2H,H−7,H−3'),7.35(1H,d,J=6.9Hz,H−8),7.97−8.07(4H,m,H−4,H−6,H−1''),8.45(1H,s,H−4'),8.68(1H,s,H−7'),10.41(1H,s,NH),10.59(1H,s,OH),12.17(1H,s,NH);MS(ESI)m/z=717.7[M+H]+。
化合物84:1H NMR(300MHz,DMSO−d6),δ(ppm):2.78(3H,s,9−Me),3.37−3.65(13H,m,6×CH2O,H−10),3.71−3.81(3H,m,CH2O,H−10),4.20(1H,t,J=4.5Hz,CH2O),4.30(1H,t,J=8.2Hz,H−1),4.52−4.62(2H,m,H−2,OH),5.05(1H,d,J=11.8Hz,H−2),7.12(2H,d,J=8.8Hz,H−3''),7.23(1H,t,J=7.7Hz,H−7),7.33(1H,d,J=6.7Hz,H−8),7.57(1H,dd,J=1.8Hz,9.7Hz,H−6'),7.73(1H,d,J=9.7Hz,H−7'),8.00(2H,d,J=8.8Hz,H−2''),8.04(1H,d,J=8.4Hz,H−6),8.09(1H,bs,H−4),8.66(1H,s,H−3'),9.46(1H,s,H−4'),10.28(1H,s,NH),10.42(1H,s,OH);MS(ESI)m/z=703[M+H]+;
化合物85:1H NMR(300MHz,DMSO−d6),δ(ppm):2.78(3H,s,9−Me),3.42(1H,t,J=10.5Hz,H−10),3.75(1H,d,J=11.0Hz,H−10),4.30(1H,t,J=8.9Hz,H−1),4.57(1H,dd,J=7.6Hz,11.8Hz,H−2),5.04(1H,d,J=11.8Hz,H−2),6.89(1H,d,J=8.7Hz,H−3''),7.23(1H,t,J=7.6Hz,H−7),7.33(1H,d,J=6.8Hz,H−8),7.57(1H,dd,J=1.8Hz,9.7Hz,H−6'),7.71(1H,d,J=9.7Hz,H−7'),7.90(2H,d,J=8.7Hz,H−2''),8.04(1H,d,J=8.1Hz,H−6),8.09(1H,bs,H−4),8.66(1H,s,H−3'),9.44(1H,s,H−4'),10.17(1H,s,OH),10.18(1H,s,NH),10.42(1H,s,OH);MS(ESI)m/z=527[M+H]+;
化合物86:1H NMR(300MHz,DMSO−d6),δ(ppm):2.78(3H,s,9−Me),3.44(1H,t,J=10.6Hz,H−10),3.76(1H,d,J=10.3Hz,H−10),4.32(1H,t,J=7.4Hz,H−1),4.58(1H,dd,J=7.4Hz,11.2Hz,H−2),4.96(1H,d,J=11.2Hz,H−2),5.93(1H,bs,NH2),6.63(2H,d,J=8.4Hz,H−3''),7.24(1H,t,J=7.6Hz,H−7),7.33(1H,d,J=6.7Hz,H−8),7.73(2H,m,H−6',H−7'),8.04(1H,d,J=8.2Hz,H−6),8.08(1H,bs,H−4),8.74(1H,s,H−3'),9.51(1H,s,H−4'),10.05(1H,s,NH),10.45(1H,s,OH);MS(ESI)m/z=526[M+H]+。
化合物41:1H NMR(400MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.50(1H,t,J=9.8Hz,H−10),3.79(1H,d,J=11.5Hz,H−10),4.36(1H,t,J=8.9Hz,H−1),4.61(1H,t,J=9.5Hz,H−2),4.92(1H,d,J=11.0Hz,H−2),6.90(2H,d,J=8.5Hz,Ar−H),7.25(1H,dd,J=7.0Hz,8.5Hz,H−7),7.35(1H,d,J=7.0Hz,H−8),7.90(2H,d,J=8.6Hz,Ar−H),7.98−8.14(6H,m,H−4,H−6,Ar−H),9.40(1H,s,トリアゾール−H),10.16(1H,s,NH),10.29(1H,s,OH),10.49(1H,s,OH);MS(ESI)m/z=554[M+H]+。
化合物63:1H NMR(300MHz,DMSO−d6),δ(ppm):2.25(6H,s,Me2N),2.67(2H,t,J=5.7Hz,CH2NMe2),2.76(3H,s,9−Me),3.57(1H,t,J=10.2Hz,H−10a),3.81(1H,m,H−10b),4.13(2H,t,J=5.7Hz,OCH2),4.33(1H,m,H−1),4.43(1H,m,H−2a),4.53(1H,m,H−2b),7.16(1H,d,J=8.3Hz,CH),7.25(3H,m,H−7',2×CH),7.35(1H,m,H−8'),7.43(1H,t,J=7.9Hz,CH),7.98(1H,s,H−4'),8.04(1H,d,J=6.8Hz,H−6'),10.53(1H,s,OH);MS(ESI)m/z=427.2[M+H]+;
化合物64:1H NMR(300MHz,DMSO−d6),δ(ppm):2.41(3H,s,CH3CO),2.76(3H,s,9−Me),3.51(1H,m,H−10a),3.79(1H,m,H−10b),4.33(2H,m,H−2a,H−1),4.49(1H,m,H−2b),7.23(1H,t,J=8.2Hz,H−7'),7.31−7.38(2H,m,CH,H−8'),7.69(1H,m,CH),7.98(1H,s,H−4'),8.02(1H,d,J=8.2Hz,H−6),10.48(1H,s,OH),12.46(1H,bs,NH);MS(ESI)m/z=407.1[M+H]+
例16
化合物66:1H NMR(300MHz,DMSO−d6),δ(ppm):2.75(3H,s,9−Me),3.60(1H,m,H−10a),3.77(1H,m,H−10b),4.00(1H,m,H−1),4.19(1H,m,H−2a),4.33(1H,m,H−2b),6.06(2H,bs,NH2),6.71(2H,d,J=8.6Hz,2×CH),7.22(1H,t,J=7.6Hz,H−7'),7.32(1H,d,J=6.6Hz,H−8'),7.39(1H,m,CH),7.59(1H,m,CH),7.80(1H,d,J=8.2Hz,CH),7.90(1H,d,J=8.6Hz,2×CH),7.95(1H,s,H−4'),8.02(1H,d,J=8.2Hz,H−6'),10.40(1H,bs,OH);MS(ESI)m/z=484.2[M+H]+。
化合物99:1H NMR(300MHz,DMSO−d6),δ(ppm):2.75(3H,s,9−Me),3.59(1H,m,H−10),3.77(1H,d,J=10.4Hz,H−10),4.01(1H,m,H−2),4.21(1H,m,H−2),4.35(1H,m,H−1),6.75(2H,d,J=8.6Hz,H−3''),7.22(1H,t,J=7.7Hz,H−7),7.33(1H,d,J=6.7Hz,H−8),7.70(1H,bs,H−4),7.72(1H,d,J=8.4Hz,H−5'),7.84(2H,d,J=8.6Hz,H−2''),7.90−8.10(2H,m,H−6,H−4'),8.37(1H,s,H−7'),10.40(1H,s,OH);MS(ESI)m/z=500[M+H]+;
化合物100:1H NMR(300MHz,DMSO−d6),δ(ppm):2.76(3H,s,9−Me),3.69(1H,m,H−10),3.78(1H,m,H−10),4.03(1H,m,H−2),4.19(1H,m,H−2),4.37(1H,m,H−1),6.68(2H,d,J=8.7Hz,H−3''),7.23(1H,dd,J=6.7Hz,8.0Hz,H−7),7.33(1H,d,J=6.7Hz,H−8),7.60(1H,bs,H−4),7.72(1H,dd,J=1.3Hz,8.4Hz,H−6'),7.84(1H,d,J=8.4Hz,H−7'),7.94(2H,d,J=8.7Hz,H−6''),8.02(1H,d,J=8.0Hz,H−2''),8.34(1H,d,J=1.3Hz,H−6),10.39(1H,bs,OH),12.53(1H,s,NH);MS(ESI)m/z=543[M+H]+。
化合物79:1H NMR(300MHz,DMSO−d6),δ(ppm):2.79(3H,s,9−Me),3.49(1H,t,J=9.4Hz,H−10),3.76(1H,d,J=10.6Hz,H−10),4.31−4.41(2H,m,H−1,H−2),4.45−4.55(1H,m,H−2),5.70(2H,bs,NH2),6.61(2H,d,J=8.8Hz,H−3''),6.89(1H,s,H−3'),7.17−7.27(2H,m,H−7,CH=CH),7.30−7.40(2H,m,H−8,H−7'),7.50(1H,dd,J=8.9Hz,2.1Hz,H−6'),7.67(1H,d,J=15.0Hz,CH=CH),7.74(2H,d,J=8.7Hz,H−2''),7.98−8.05(2H,m,H−6,H−4'),8.21(1H,bs,H−4),9.66(1H,s,NH),10.44(1H,s,OH),11.59(1H,s,NH);MS(ESI)m/z=551[M+H]+;
化合物80:1H NMR(300MHz,DMSO−d6),δ(ppm):2.78(3H,s,9−Me),3.47(1H,m,H−10a),3.75(1H,d,J=11.1Hz,H−10b),3.83(3H,s,OMe),4.34(2H,m,H−2a,H−1),4.53(1H,m,H−2b),6.85(1H,d,J=2.0Hz,CH),7.21(1H,t,J=7.9Hz,H−7'),7.31(1H,s,H−8'),7.37(1H,d,J=15.3Hz,=CH−),7.57(1H,d,J=3.2Hz,CH),7.65(1H,d,J=15.3Hz,=CH−),8.03(1H,d,J=7.9Hz,H−6'),8.07(1H,d,J=3.2Hz,CH),8.21(1H,bs,H−4'),10.43(1H,s,OH),12.12(1H,s,NH);MS(ESI)m/z=448.1[M+H]+
例19
例21
化合物104:1H NMR(300MHz,DMSO),δ(ppm):2.26(3H,s,Me),2.78(3H,s,9−Me),3.46(1H,t,J=11.0Hz),3.78(1H,d,J=11.7Hz),4.29(1H,t,J=7.75Hz,H−2),4.44(1H,d,J=10.7Hz,H−2),4.60(1H,m,H−1),6.60(1H,d,J=16.1Hz),7.21(1H,d,J=7.0Hz,H−7),7.25(1H,s),7.33(1H,d,J=6.9Hz,H−8),7.52(1H,d,J=3.0Hz,H−12),7.60(1H,d,J=16.3Hz,H−14),7.98(1H,s,H−4),8.02(1H,d,J=8.5Hz,H−6),10.41(1H,s,NH);MS(ESI)m/z=409.2[M+H]+。
1 Boger, D.L.; Johnson, D.S.; Wrasidlo, W. Bioorg. Med. Chem. Lett. 1994, 4, 631-636.
2 McGovren, J.P., Clarke, G.L., Pratt, E.A., DeKoning, T.F. J. Antibiot. 1984, 37, 63-70.
3 Carter, P.; Smith, L.; Ryan, M. Endocr.-Relat. Cancer 2004, 11, 659-687.
4 Bagshawe, K.D. Drug Dev. Res. 1995, 34, 220-230.
5 Melton, R.; Connors, T.; Knox, R.J. S.T.P. Pharma Sciences, 1999, 13-33.
6 Huber, B.E.; Richards, C.A.; Krenitsky, T.A. Proc. Natl. Acad. Sci. USA, 1991, 88, 8039-8043.
7 Bagshawe, K.D.; Springer, C.J.; Searle, F.; Antoniw, P.; Sharma, S.K.; Melton, R.G.; Sherwood, R.F. Br. J. Cancer, 1988, 58, 700-703.
8 Duncan, R. Nat. Rev. Drug Discov. 2003, 2, 347-360.
9 Toki, B.E.; Cerveny, C.G.; Wahl, A.F.; Senter, P.D. J. Org. Chem., 2002, 67, 1866-1872.
10 See for some recently disclosed cyclization spacers for example WO 2005/079398, WO 2005/105154, and WO 2006/012527.
11 Greenwald, R.B., Choe, Y.H., McGuire, J., Conover, C.D. Adv. Drug Delivery Rev. 2003, 55, 217-250.
12 Kingsbury, W.D.; Boehm; J.C.; Mehta, R.J.; Grappel, S.F.; Gilvarg, C. J. Med. Chem. 1984, 27, 1447-1451.
13 Greenwald, R. B.; Zhao, H.; Yang, K.; Reddy, P.; Martinez, A. J. Med. Chem. 2004, 47, 726-734.
14 (a) Franke, A. E.; Sievers, E.L.; and Scheinberg, D. A. Cancer Biother. Radiopharm. 2000, 15, 459-476.
(b) Murray, J. L. Semin. Oncol. 2000, 27, 2564-2570. (c) Breitling, F., and Dubel, S., Recombinant Antibodies,
John Wiley and Sons, New York, 1998.
15 Ringsdorf, H. J. Polym. Sci., Polym. Symp. 1975, 51, 135-153.
16 Elvira, C.; Gallardo, A.; San Roman, J.; Cifuentes, A. Molecules 2005, 10, 114-125.
17 Remington's Pharmaceutical Science (15th ed., Mack Publishing, Easton, PA, 1980) (その全体を参照によりすべて本明細書に組み込む)
Claims (10)
- 式(I)の化合物:
(ここで
DBは以下に示されるDNA結合部分であり、
(Re、RfおよびRgは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-15アルキル,C1-15へテロアルキル,C3-15シクロアルキル,C1-15ヘテロシクロアルキル,C5-15アリールまたはC1-15ヘテロアリールから選択され(eeは1から1000までで選択され、X13はO,S,およびNRf1から選択される)(Rf1およびRe1は独立してHおよびC1-3アルキルから選択される)、R e ,RfおよびRgのうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する))、
X3はO,S,C(R15)R15',−C(R15)(R15')−C(R15'')(R15''')−,−N(R15)−N(R15')−,−C(R15)(R15')−N(R15'')−,−N(R15'')−C(R15)(R15')−,−C(R15)(R15')−O−,−O−C(R15)(R15')−,−C(R15)(R15')−S−,−S−C(R15)(R15')−,−C(R15)=C(R15')−,=C(R15)−C(R15')=,−N=C(R15')−,=N−C(R15')=,−C(R15)=N−,=C(R15)−N=,−N=N−,=N−N=,CR15,NおよびNR15から選択され;
X4はO,S,C(R16)R16',NR16,NおよびCR16から選択され;
X5はO,S,C(R17)R17',NOR17およびNR17から選択され(R17およびR17'は独立してHおよび任意に置換されたC1-8アルキルまたはC1-8へテロアルキルから選択され、あらゆる他の置換基と結合しない);
X6はCR11,CR11(R11'),N,NR11,OおよびSから選択され;
X7はCR8,CR8(R8'),N,NR8,OおよびSから選択され;
X8はCR9,CR9(R9'),N,NR9,OおよびSから選択され;
X9はCR10,CR10(R10'),N,NR10,OおよびSから選択され;
X11はC,CR21およびNから選択され;
X12はC,CR22およびNから選択され;
X34はC,CR23およびNから選択され;
R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R 21 ,R22およびR23はそれぞれ独立してH,OH,SH,NH2,N3,NO2,NO,CF3,CN,C(O)NH2,C(O)H,C(O)OH,ハロゲン,Rh,SRh,S(O)Rh,S(O)2Rh,S(O)ORh,S(O)2ORh,OS(O)Rh,OS(O)2Rh,OS(O)ORh,OS(O)2ORh,ORh,NHRh,N(Rh)Ri,+N(Rh)(Ri)Rj,P(O)(ORh)(ORi),OP(O)(ORh)(ORi),SiRhRiRj,C(O)Rh,C(O)ORh,C(O)N(Rh)Ri,OC(O)Rh,OC(O)ORh,OC(O)N(Rh)Ri,N(Rh)C(O)Ri,N(Rh)C(O)ORi,N(Rh)C(O)N(Ri)R j から選択され、
(Rh,RiおよびRjは独立してHおよび任意に置換された(CH2CH2O)eeCH2CH2X13Re1,C1-15アルキル,C1-15へテロアルキル,C3-15シクロアルキル,C1-15へテロシクロアルキル,C5-15アリールまたはC1-15ヘテロアリールから選択され、Rh,RiおよびRjのうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成する)
またはR8+R8'および/若しくはR9+R9’および/若しくはR10+R10'および/若しくはR11+R11'および/若しくはR15+R15'および/若しくはR15''+R15'''および/若しくはR16+R16'は独立して=O,=S,=NORh1,=C(Rh1)Rh2および=NRh1から選択され(Rh1およびRh2は独立してHおよび任意に置換されたC1-3アルキルから選択される)、R8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R 21 ,R22およびR23のうち2つ以上は任意に1つ以上の結合により結合して1つ以上の任意に置換された炭素環および/またはヘテロ環を形成し;
DB1における環Bはヘテロ環である。) - R5がメチル、エチル、プロピル、イソプロピル、ニトロ、CF3、F、Cl、Br、シアノ、メトキシ、エトキシ、プロポキシ、イソプロポキシ、アミノ(NH2)、メチルアミノ、ホルミル、ヒドロキシメチルおよびジメチルアミノから選択される請求項1または2に記載の化合物。
- 置換基R 5 ,R 8,R8',R9,R9',R10,R10',R11,R11',R15,R15',R15'',R15''',R16,R16',R 21 ,R22およびR23の少なくとも1つがトリアゾール部分を含む請求項1ないし4のいずれか1項に記載の化合物。
- 式(III)の化合物:
(ここで
V2は、抗体若しくは抗体断片またはその誘導体であり;
各L2 はV 2をLに連結する
各LはL 2を1つ以上のV1および/若しくはYに連結する
および および
から選ばれる連結基であり;
各V1はタンパク質分解酵素、カテプシン、カテプシンB、β−グルクロニダーゼ、ガラクトシダーゼ、前立腺特異抗原(PSA)、ウロキナーゼ型プラスミノゲン活性化酵素(u−PA)、マトリックスメタロプロテアーゼのファミリーのメンバー、または指向性酵素プロドラッグ療法を用いて局在化させた酵素により切断されうる基質を含むか、またはV1が、低酸素条件下での還元により、ニトロ還元酵素による還元により若しくは酸化により切断または変換されうる部分を含み;
各Yは
R 117 、R 118 、R 119 およびR 120 は独立して、H、OH、SH、NH 2 、N 3 、NO 2 、NO、CF 3 、CN、C(O)NH 2 、C(O)H、C(O)OH、ハロゲン、R z 、SR z 、S(O)R z 、S(O) 2 R z 、S(O)OR z 、S(O) 2 OR z 、OS(O)R z 、OS(O) 2 R z 、OS(O)OR z 、OS(O) 2 OR z 、OR z 、NHR z 、N(R z )R z1 、 + N(R z )(R z1 )R z2 、P(O)(OR z )(OR z1 )、OP(O)(OR z )(OR z1 )、C(O)R z 、C(O)OR z 、C(O)N(R z1 )R z 、OC(O)R z 、OC(O)OR z 、OC(O)N(R z )R z1 、N(R z1 )C(O)R z 、N(R z1 )C(O)OR z 、およびN(R z1 )C(O)N(R z2 )R z から選択され、ここで、R z 、R z1 、およびR z2 は独立してHおよび任意に置換された(CH 2 CH 2 O) ee CH 2 CH 2 X 13 R e1 、C 1−20 アルキル、C 1−20 ヘテロアルキル、C 3−20 シクロアルキル、C 1−20 ヘテロシクロアルキル、C 5−20 アリール、またはC 1−20 ヘテロアリールから選択され、ここで、eeは、1〜1000から選択され、X 13 は、O、S、およびNR f1 から選択され、並びに、R f1 およびR e1 は独立してHおよびC 1−3 アルキルから選択され、R z 、R z1 、およびR z2 の二以上は、任意に一以上の結合によって連結されて一以上の任意に置換された炭素環および/またはヘテロ環を形成し、置換基R 117 、R 118 、R 119 およびR 120 の二以上は、任意に一以上の結合によって連結されて一以上の任意に置換された炭素環および/またはヘテロ環を形成し;
、かつV1、任意にL、および1つ以上のZと連結し;
pは分岐度を示す数で、1,2,3,4,6,8または9であり;
qは分岐度を示す数で、1〜20の整数であり
zはZについての結合部位の合計数以下である正の整数であり;
各Zは独立して請求項1ないし6のいずれかの化合物であり、
各Zは独立して、OH基のO通じてYに結合し;並びにYは、Yの一部であるω−アミノアミノカルボニル環化スペーサーを介してOに結合する)。 - 以下である請求項7記載の化合物:
(ここで、R 5 およびDBは先に定義した通りであり、V 1 は、バリルシトルリン、バリルリジン、フェニルアラニルリジン、アラニルフェニルアラニルリジン、およびD−アラニルフェニルアラニルリジンから選択され、fは1または2であり、Lは
qは1から20までにわたり、rr、rr'、およびrr''は各々独立して0から8までにわたり、各X 40 およびX 41 は独立してO、S、およびNR 135 から選択され、ここで、R 135 はHおよびC 1-3 アルキルから選択され、各uu、uu'、およびuu''は独立して0および1から選択され、Abは抗体またはその断片もしくは誘導体である。) - 式(IV)の化合物
(ここで、
RMが以下の反応部分であり、
X35はハライド、ヒドロキシ、OC(O)RddおよびOC(O)ORddから選択されるか、
X36はハライド、メシルオキシ、トリフリルオキシおよびトシルオキシから選択され、Rddは任意に置換されたC1-10アルキル、C1-10ヘテロアルキル、C3-10シクロアルキル、C1-10ヘテロシクロアルキル、C5-10アリールおよびC1-10ヘテロアリールから選択される、
L,V1,Y,Z,pおよびzは請求項7で定義した通りであるが、ただしLはここではRMを1つ以上のV1および/またはYに連結しており、V1,YおよびZは保護基を有してよい。) - 請求項1ないし9のいずれか1項に記載の化合物と薬学的に許容される担体を含む薬剤組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11076508P | 2008-11-03 | 2008-11-03 | |
US61/110,765 | 2008-11-03 | ||
US14021308P | 2008-12-23 | 2008-12-23 | |
US61/140,213 | 2008-12-23 | ||
US17023109P | 2009-04-17 | 2009-04-17 | |
US61/170,231 | 2009-04-17 | ||
PCT/NL2009/050660 WO2010062171A2 (en) | 2008-11-03 | 2009-11-03 | Novel cc-1065 analogs and their conjugates |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014223435A Division JP5905559B2 (ja) | 2008-11-03 | 2014-10-31 | 新規cc−1065類似体およびその複合体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012513954A JP2012513954A (ja) | 2012-06-21 |
JP5677970B2 true JP5677970B2 (ja) | 2015-02-25 |
Family
ID=41722971
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011535528A Active JP5677970B2 (ja) | 2008-11-03 | 2009-11-03 | 新規cc−1065類似体およびその複合体 |
JP2014223435A Expired - Fee Related JP5905559B2 (ja) | 2008-11-03 | 2014-10-31 | 新規cc−1065類似体およびその複合体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014223435A Expired - Fee Related JP5905559B2 (ja) | 2008-11-03 | 2014-10-31 | 新規cc−1065類似体およびその複合体 |
Country Status (19)
Country | Link |
---|---|
US (2) | US8889868B2 (ja) |
EP (1) | EP2344478B1 (ja) |
JP (2) | JP5677970B2 (ja) |
CN (2) | CN106967062A (ja) |
AU (2) | AU2009320481C1 (ja) |
BR (1) | BRPI0921687A8 (ja) |
CA (1) | CA2742568C (ja) |
CY (1) | CY1119696T1 (ja) |
DK (1) | DK2344478T3 (ja) |
ES (1) | ES2647317T3 (ja) |
HR (1) | HRP20171629T1 (ja) |
HU (1) | HUE035798T2 (ja) |
LT (1) | LT2344478T (ja) |
MX (1) | MX2011004625A (ja) |
NO (1) | NO2344478T3 (ja) |
PL (1) | PL2344478T3 (ja) |
PT (1) | PT2344478T (ja) |
RU (2) | RU2628069C2 (ja) |
WO (1) | WO2010062171A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013525347A (ja) * | 2010-04-21 | 2013-06-20 | シンタルガ・ビーブイ | Cc−1065類似体の新規の複合体および二官能性リンカー |
US9815784B2 (en) | 2008-11-03 | 2017-11-14 | Syntarga B.V. | CC-1065 analogs and their conjugates |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011157741A2 (en) | 2010-06-15 | 2011-12-22 | Genmab A/S | Human antibody drug conjugates against tissue factor |
JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
JP6177231B2 (ja) | 2011-04-20 | 2017-08-09 | ゲンマブ エー/エス | Her2に対する二重特異性抗体 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
CA3182462A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
AU2012322095B2 (en) | 2011-10-14 | 2017-06-29 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases |
US8586792B2 (en) | 2011-12-28 | 2013-11-19 | Divi's Laboratories Ltd. | Process for the preparation of 4-iodo-3-nitrobenzamide |
CA2868447C (en) * | 2012-03-30 | 2020-09-15 | The Scripps Research Institute | Cyclic prodrugs of duocarmycin analogs |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CN113735967A (zh) | 2013-01-10 | 2021-12-03 | 根马布私人有限公司 | 人类IgG1 FC区变体及其用途 |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
CA3211863A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CN111138543A (zh) | 2013-03-15 | 2020-05-12 | Xencor股份有限公司 | 异二聚体蛋白 |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
CA3093606A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
EA036927B1 (ru) | 2013-10-11 | 2021-01-15 | Оксфорд Биотерепьютикс Лтд | Конъюгированные антитела против ly75 для лечения рака |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
AU2015205509B2 (en) | 2014-01-10 | 2019-08-15 | Byondis B.V. | Duocarmycin ADCs showing improved in vivo antitumor activity |
EP3092010B1 (en) | 2014-01-10 | 2018-07-11 | Synthon Biopharmaceuticals B.V. | Method for purifying cys-linked antibody-drug conjugates |
CA2935430C (en) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in treatment of endometrial cancer |
CN106459055B (zh) | 2014-01-27 | 2019-11-01 | 辉瑞大药厂 | 双功能细胞毒类药剂 |
SG10202008629XA (en) | 2014-03-28 | 2020-10-29 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
SG10201913977TA (en) | 2014-05-22 | 2020-03-30 | Synthon Biopharmaceuticals Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
ES2738211T3 (es) | 2014-06-05 | 2020-01-20 | Synthon Biopharmaceuticals Bv | Procedimiento mejorado de preparación de profármacos a base de duocarmicina |
EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
LT3169706T (lt) | 2014-07-11 | 2020-03-25 | Genmab A/S | Antikūnai, besirišantys prie axl |
US20160060360A1 (en) | 2014-07-24 | 2016-03-03 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US20170320965A1 (en) * | 2014-09-22 | 2017-11-09 | Synthon Biopharmaceuticals B.V. | Pan-reactive antibodies to duocarmycins |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EA037065B1 (ru) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Гетеродимерные антитела, связывающие cd3 и cd38 |
LT3223845T (lt) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
US10870706B2 (en) | 2015-03-20 | 2020-12-22 | Pfizer Inc. | Bifunctional cytotoxic agents containing the CTI pharmacophore |
AU2016292759B2 (en) | 2015-07-10 | 2021-05-20 | Byondis B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
DE102016105449A1 (de) * | 2015-10-29 | 2017-05-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Bifunktionale Prodrugs |
JP6486316B2 (ja) | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Industrial Technology Research Institute | 抗体−薬物複合体(adc)およびそれを形成するための方法 |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
WO2017156179A1 (en) * | 2016-03-09 | 2017-09-14 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
PL3884939T3 (pl) | 2016-03-09 | 2024-02-26 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
WO2017156181A1 (en) * | 2016-03-09 | 2017-09-14 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
EA037848B1 (ru) | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3525826B1 (en) | 2016-10-11 | 2020-07-22 | Byondis B.V | Non-linear self-immolative linkers and conjugates thereof |
MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
SG11202005732XA (en) | 2017-12-19 | 2020-07-29 | Xencor Inc | Engineered il-2 fc fusion proteins |
JP2021510740A (ja) | 2018-01-24 | 2021-04-30 | ゲンマブ ビー.ブイ. | ポリペプチド変種およびそれらの用途 |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
CR20210047A (es) | 2018-07-02 | 2021-05-21 | Amgen Inc | Proteína de unión al antígeno anti-steap1 |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
CA3118788A1 (en) | 2018-11-09 | 2020-05-14 | Carolus Johannes Edgar VAN DEN HOEF | Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods |
KR20210134725A (ko) | 2019-03-01 | 2021-11-10 | 젠코어 인코포레이티드 | Enpp3과 cd3에 결합하는 이종이량체 항체 |
EP3963085A4 (en) * | 2019-05-01 | 2022-09-14 | The University of North Carolina at Chapel Hill | RNA-BINDING PROTEIN INHIBITORS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
CN113766933A (zh) * | 2019-06-28 | 2021-12-07 | 上海复旦张江生物医药股份有限公司 | 一种抗体偶联药物、其中间体、制备方法及应用 |
CN115052663A (zh) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
CA3165711A1 (en) | 2020-02-06 | 2021-08-12 | Johannes Henricus Matthias Schellens | Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
CN116209476A (zh) | 2020-07-06 | 2023-06-02 | 拜奥迪斯私人有限公司 | 抗叶酸剂接头-药物和抗体-药物缀合物 |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
KR20240013732A (ko) | 2021-05-26 | 2024-01-30 | 옥스포드 바이오테라퓨틱스 리미티드 | 항-cd205 항체 및 면역 체크포인트 억제제를 포함하는 약학적 조합물 |
KR20240027761A (ko) | 2021-06-28 | 2024-03-04 | 비온디스 비.브이. | 인항원을 포함하는 접합체 및 요법에서의 이의 용도 |
WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
WO2023126297A1 (en) | 2021-12-30 | 2023-07-06 | Byondis B.V. | Antifolate linker-drugs and antibody-drug conjugates |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2098331A (en) | 1981-05-12 | 1982-11-17 | Sangamo Weston Controls | Parallel motion displacement transducers |
CA1238907A (en) * | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
WO1988004659A2 (en) | 1986-12-19 | 1988-06-30 | The Upjohn Company | Novel cc-1065 analogs |
MX9203460A (es) * | 1988-09-12 | 1992-09-01 | Upjohn Co | Nuevos analogos cc-1065 que tienen dos subunidades cpi. |
AU632288B2 (en) | 1988-09-12 | 1992-12-24 | Pharmacia & Upjohn Company | Novel cc-1065 analogs having two cpi subunits |
AU648313B2 (en) * | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
JP3514490B2 (ja) * | 1992-08-21 | 2004-03-31 | 杏林製薬株式会社 | トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法 |
US5670492A (en) * | 1994-04-01 | 1997-09-23 | Kyowa Hakko Kogyo Co., Ltd. | DC-89 derivatives |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
US5646298A (en) | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
GB9516943D0 (en) | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
CA2233936A1 (en) | 1995-10-03 | 1997-04-10 | The Scripps Research Institute | Cbi analogs of cc-1065 and the duocarmycins |
JP2000506168A (ja) | 1996-03-08 | 2000-05-23 | ザ スクリップス リサーチ インスティテュート | Cc―1065及びデュオカマイシンのmcbi類似体 |
US5843937A (en) * | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
WO1997045411A1 (en) | 1996-05-31 | 1997-12-04 | The Scripps Research Institute | Analogs of cc-1065 and the duocarmycins |
NZ334344A (en) | 1996-09-12 | 2000-08-25 | Cancer Res Campaign Tech | benzo[e]indole and pyrrolo[3,2-e]indole compounds and their use as prodrugs |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
GB9625913D0 (en) | 1996-12-13 | 1997-01-29 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their seco precursors,and their use as prodrugs |
WO1998025900A1 (fr) | 1996-12-13 | 1998-06-18 | Shionogi & Co., Ltd. | Composes presentant une activite antitumorale |
JP2002503228A (ja) | 1997-05-22 | 2002-01-29 | ザ スクリップス リサーチ インスティテュート | デュオカルマイシンおよびcc−1065の類似体 |
WO1999019298A1 (en) | 1997-10-14 | 1999-04-22 | The Scripps Research Institute | iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS |
US7214685B2 (en) | 2000-05-02 | 2007-05-08 | Lutz F. Tietze | Prodrugs for a selective cancer therapy |
AU2001262974A1 (en) | 2000-05-03 | 2001-11-12 | The Scripps Research Institute | Dna alkylating agent and activation thereof |
ATE310724T1 (de) | 2000-09-19 | 2005-12-15 | Taiho Pharmaceutical Co Ltd | Zusammensetzungen und verfahren zur verwendung achirale analoge von cc1065 und den duocarmycinen |
US7064117B2 (en) | 2001-01-24 | 2006-06-20 | Auckland Uniservices Limited | Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium |
US7192977B2 (en) * | 2001-02-22 | 2007-03-20 | School Of Pharmacy | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
DE60223544T2 (de) | 2001-02-22 | 2008-09-25 | University Of Bradford, Bradford | Pyrrolo-indol- und pyrrolo-chinolin-derivate als prodrugs zur tumorbehandlung |
WO2002067937A1 (en) | 2001-02-22 | 2002-09-06 | School Of Pharmacy, University Of London | Indoline and tetrahydro-quinolines as prodrugs for tumour treatment |
EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
WO2002096910A1 (en) * | 2001-05-31 | 2002-12-05 | Medarex, Inc. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
EP1423110A4 (en) | 2001-09-07 | 2005-04-27 | Scripps Research Inst | CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES |
US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
US7235578B2 (en) * | 2002-05-17 | 2007-06-26 | Auckland Uniservices Limited | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom |
WO2004043493A1 (en) * | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
EP2517730A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
WO2004069201A2 (en) | 2003-02-03 | 2004-08-19 | Medlogics Device Corporation | Compounds useful in coating stents to prevent and treat stenosis and restenosis |
EP2289559B1 (en) | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US20050026987A1 (en) * | 2003-05-13 | 2005-02-03 | The Scripps Research Institute | CBI analogues of the duocarmycins and CC-1065 |
WO2005032594A2 (en) | 2003-10-03 | 2005-04-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alkylators linked to polyamides as dna binding agents |
US7282590B2 (en) | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
CA2562527A1 (en) | 2004-04-21 | 2005-11-10 | Alza Corporation | Polymer conjugate releasable under mild thiolytic conditions |
US20050239864A1 (en) | 2004-04-23 | 2005-10-27 | Yuqiang Wang | Novel tumor-selective chemotherapeutic agents |
US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
EP1765409A2 (en) | 2004-06-30 | 2007-03-28 | Novartis AG | Conjugates of antibody and duocarmycin derivatives as antitumor agents |
CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
AU2005289453A1 (en) | 2004-09-27 | 2006-04-06 | Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health | Modulating MxA expression |
NZ536107A (en) | 2004-10-22 | 2007-06-29 | Auckland Uniservices Ltd | Nitrobenzindoles and their use in cancer therapy |
WO2006090261A1 (en) | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2617907A1 (en) * | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
US20080279868A1 (en) * | 2005-09-26 | 2008-11-13 | Medarex, Inc. | Antibody-Drug Conjugates and Methods of Use |
DK1940789T3 (da) * | 2005-10-26 | 2012-03-19 | Medarex Inc | Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger |
CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
US8940784B2 (en) * | 2006-02-02 | 2015-01-27 | Syntarga B.V. | Water-soluble CC-1065 analogs and their conjugates |
EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
KR20090088946A (ko) | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | 씨디70에 결합하는 인간 항체 및 이의 용도 |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
AR065404A1 (es) | 2007-02-21 | 2009-06-03 | Medarex Inc | Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
ES2433379T3 (es) | 2007-08-01 | 2013-12-10 | Syntarga B.V. | Análogos de CC-1065 sustituidos y sus conjugados |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
WO2009064908A1 (en) | 2007-11-13 | 2009-05-22 | The Scripps Research Institute | Cbi derivatives subject to reductive activation |
WO2009073546A2 (en) | 2007-11-30 | 2009-06-11 | Medarex, Inc. | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) |
EP2211908A2 (en) | 2007-11-30 | 2010-08-04 | Bristol-Myers Squibb Company | Conjugates of anti-rg-1 antibodies |
TW200938224A (en) | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
US20090162372A1 (en) * | 2007-11-30 | 2009-06-25 | Medarex, Inc. | Fibronectin ed-b antibodies, conjugates thereof, and methods of use |
KR101764081B1 (ko) | 2008-04-30 | 2017-08-01 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
NZ571028A (en) | 2008-09-03 | 2011-01-28 | Auckland Uniservices Ltd | Nitrobenzindole compounds and their use in cancer treatment |
US8546425B2 (en) | 2008-09-17 | 2013-10-01 | Purdue Research Foundation | Folate receptor binding conjugates of antifolates |
CN106967062A (zh) | 2008-11-03 | 2017-07-21 | 辛塔佳股份有限公司 | 新型cc‑1065类似物及其缀合物 |
US8507195B2 (en) | 2009-08-20 | 2013-08-13 | The Regents Of The University Of Colorado | MiRNAs dysregulated in triple-negative breast cancer |
TR201802539T4 (tr) | 2010-04-21 | 2018-03-21 | Syntarga Bv | CC-1065 analoglarının ve bifonksiyonel bağlayıcıların konjugatları. |
IL309917A (en) | 2011-10-14 | 2024-03-01 | Genentech Inc | Pertuzumab and Trastuzumab for use in treatment |
AU2015205509B2 (en) | 2014-01-10 | 2019-08-15 | Byondis B.V. | Duocarmycin ADCs showing improved in vivo antitumor activity |
CA2935430C (en) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in treatment of endometrial cancer |
-
2009
- 2009-11-03 CN CN201611028228.7A patent/CN106967062A/zh active Pending
- 2009-11-03 US US13/126,920 patent/US8889868B2/en active Active
- 2009-11-03 PL PL09748515T patent/PL2344478T3/pl unknown
- 2009-11-03 ES ES09748515.5T patent/ES2647317T3/es active Active
- 2009-11-03 MX MX2011004625A patent/MX2011004625A/es active IP Right Grant
- 2009-11-03 DK DK09748515.5T patent/DK2344478T3/da active
- 2009-11-03 NO NO09748515A patent/NO2344478T3/no unknown
- 2009-11-03 RU RU2015125006A patent/RU2628069C2/ru active
- 2009-11-03 RU RU2011122487/04A patent/RU2562232C2/ru active
- 2009-11-03 LT LTEP09748515.5T patent/LT2344478T/lt unknown
- 2009-11-03 JP JP2011535528A patent/JP5677970B2/ja active Active
- 2009-11-03 WO PCT/NL2009/050660 patent/WO2010062171A2/en active Application Filing
- 2009-11-03 EP EP09748515.5A patent/EP2344478B1/en active Active
- 2009-11-03 PT PT97485155T patent/PT2344478T/pt unknown
- 2009-11-03 AU AU2009320481A patent/AU2009320481C1/en active Active
- 2009-11-03 CA CA2742568A patent/CA2742568C/en active Active
- 2009-11-03 BR BRPI0921687A patent/BRPI0921687A8/pt not_active Application Discontinuation
- 2009-11-03 HU HUE09748515A patent/HUE035798T2/en unknown
- 2009-11-03 CN CN2009801537336A patent/CN102317283A/zh active Pending
-
2014
- 2014-10-28 US US14/526,462 patent/US9815784B2/en active Active
- 2014-10-31 JP JP2014223435A patent/JP5905559B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-13 AU AU2015213344A patent/AU2015213344B2/en not_active Ceased
-
2017
- 2017-10-24 HR HRP20171629TT patent/HRP20171629T1/hr unknown
- 2017-12-18 CY CY20171101318T patent/CY1119696T1/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9815784B2 (en) | 2008-11-03 | 2017-11-14 | Syntarga B.V. | CC-1065 analogs and their conjugates |
JP2013525347A (ja) * | 2010-04-21 | 2013-06-20 | シンタルガ・ビーブイ | Cc−1065類似体の新規の複合体および二官能性リンカー |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5905559B2 (ja) | 新規cc−1065類似体およびその複合体 | |
JP6193433B2 (ja) | Cc−1065類似体の新規の複合体および二官能性リンカー | |
AU2009320481B9 (en) | Novel CC-1065 analogs and their conjugates | |
EP2173739B1 (en) | Substituted cc-1065 analogs and their conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121018 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140212 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140611 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141031 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5677970 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |